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Cellular Interactions Occurring in the Hilar Lymph Node Mediate the Development of
Tolerance in an Ovalbumin - Induced Murine Model of Allergic Airway Disease

Prabitha Natarajan, Ph.D.
University of Connecticut, 2013

In a biphasic, ovalbumin (OVA)-induced murine asthma model where allergic airway disease
(AAD) is followed by resolution and the development of local inhalational tolerance (LIT),
transforming growth factor (TGF)-β expressing CD5+ B cells were selectively expanded locally
in hilar lymph nodes (HLN) of LIT mice. When adoptively transferred, CD5+ B cells isolated
from HLN of LIT mice but not CD5– B cells inhibited airway eosinophilia, in this OVA model.
These CD5+ regulatory B cells (Breg) and CD4+ Foxp3+ T cells demonstrated similar increases
in expression of chemokine receptors (CXCR4 and CXCR5) and localized in HLN B cell zones
of LIT mice. LIT HLN CD5+ B cells, but not LIT HLN CD5– B cells, induced expression of
Foxp3 in CD4+ CD25– T cells in vitro. In the mesenteric lymph node (MLN), the frequencies of
Foxp3+ Tregs, CD5+ B cells and OVA-specific CD8+ T cells do not increase at AAD or LIT.
Further, Foxp3+ Tregs did not localize in the MLN B cell zones of LIT mice. Thus, the
expansion and preferential localization of regulatory cells in B cell zones occurs only in the HLN
and is not observed in other mucosal sites such as the MLN. Studies with transgenic mice (HEL
mice) expressing B cell receptor specific to the antigen- hen egg lysozyme (HEL) demonstrated
that AAD develops normally in these mice in response the OVA antigen. Also, there was the
induction of LIT in the HEL mice and the LIT HLN B cells from these mice induced expression
of Foxp3 in CD4+ CD25– T cells in vitro similar to wild-type mice. Thus, Bregs are induced
normally in the HLN upon chronic daily antigen exposure in an antigen non-specific manner.
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CHAPTER 1
INTRODUCTION

A) Asthma
i) Prevalence of Asthma

Makes most of us breathless

The term asthma comes from a Greek verb (aazein) ἅσθμα, meaning to pant or sharp
breath. The earliest use of the word asthma as a medical term dates back to 460-360 BC, in the
Corpus Hippocraticum. Whether Hippocrates used the term as an autonomous clinical entity or a
symptom is not known (1). Until the mid 1960s, asthma was largely regarded as a disease
induced by bronchial spasms that could be treated with a variety of bronchodilators. The overdependence on bronchodilators is thought to be one of the major underlying factors that lead to
the epidemic of asthma related deaths in Australia, the United States and the United Kingdom
with the peak occurring in the mid 1960s(2). The hallmark discovery of the immunoglobin IgE
as a substance that passively transferred allergy provided the crucial link between asthma,
immunity and inflammation (3, 4). Thus it was not until the 1980s that there was a clearer
understanding of the early events in asthma; which subsequently led to the re-definition of
asthma as an inflammatory condition triggered by exposure to various allergens (5, 6).
The incidence of the disease has risen steadily through the decades and as of 2011, it is
reported that ~300 million people have been diagnosed with asthma worldwide (7, 8). Asthma is
the most common chronic disease among children and is more common in developed nations.
The Center for Disease Control and Prevention (CDC) reports one in twelve people in the US
have asthma and the number is growing each year. Approximately 2.1 million individuals with
asthma visit the emergency room each year and 3,400 individuals die of asthma each year in the
1

United States(9). The annual direct health care cost of asthma is approximately $50 billion with
indirect health costs adding another $6 billion and these numbers are skyrocketing each year
(10). Thus, it is extremely important to improve the available treatment options to prevent deaths
related to asthma and improve the quality of life of several million individuals. Understanding
the mechanisms of the pathogenesis of asthma is required for the management of this growing
disease.
There are several theories regarding the recent increased rate of asthma but none have
been fully accepted. Perhaps, the hygiene hypothesis best explains the increasing prevalence of
asthma in developed countries as a direct effect of reduced exposure to non-pathogenic microbes
during childhood (11). The reduced exposure to bacteria and viruses in developed countries
correlates with increased cleanliness, decreased size of family and increased use of antibiotics
(12, 13). The lower prevalence of asthma among farmers and in households with pets where
there is increased exposure to microbes, acts as supporting evidence for the hygiene hypothesis
(14). Another newly proposed theory is the correlation of the asthma epidemic with the
increased use of acetaminophen in place of aspirin in the 1980s, due to the association of aspirin
with Reyes Syndrome. In certain organs of the body such as lung and liver, acetaminophen is
activated by tissue specific enzymes resulting in the presence of highly reactive toxic oxygen
species. Under normal conditions, cellular defense mechanisms protect against such reactive
oxygen molecules; however, when stressed as in the case of exposure to environmental toxins
(i.e., diesel exhaust, tobacco smoke), extensive tissue cell damage can readily occur leading to
enhanced inflammation and asthma (15).

2

ii) Pathogenesis

Nothing is simple

Asthma is a respiratory disease characterized by reversible narrowing and obstruction of the
conducting airways, with multifactorial and overlapping biological mechanisms typically
manifested via several distinct characteristic pathways: inflammation, increased mucus
secretion, smooth muscle hypertrophy and bronchoconstriction. Each of these pathways alone
can result in airway obstruction but they often occur together, contributing to the degree of the
obstruction and to difficulty in therapeutic management. The obstruction of airflow is clinically
manifested by disease symptoms such as shortness of breath, wheezing, coughing (often
observed in young children, <5 years of age) and chest tightness. Asthma is sub-divided into
two major categories, allergic or non-allergic. Exposure to pollutants and allergens such as
pollen, cat dander, house dust mites, molds, cockroach debris and several food allergens like
peanuts, typically account for a majority of reported cases of allergic asthma. Causes for nonallergic asthma are usually “intrinsic”; such as, induced stress (exercise or mental), genetic predisposition (polymorphisms in TGF-β, TNF-, ADAM33), and sudden fluctuations in
temperature.

3

iii) Hallmark Characteristics

Sensitive “unhappy” narrow airways

1. Airway inflammation: Asthma is considered a multi-cellular process(16, 17) orchestrated
predominantly by the recruitment and activation of lymphocytes (T and B cells), eosinophils,
mast cells, neutrophils, and dendritic cells (antigen presenting cells). The activation of the
CD4+ Th2 effector T lymphocyte is a crucial contributor to the pathogenesis of asthma, as
they can directly contribute to several prominent features of asthma via secretion of Th2
cytokines namely, IL-4 (required for isotype class switching of B cells to synthesize IgE),
IL-5 (chemotactic factor for eosinophils), IL-13 (stimulates mucus production) and
leukotrienes such as LTB4 (chemotactic factor for neutrophils) and LTC4, LTD4 and LTE4
(potent bronchoconstrictors) (18-20). Both systemic and lung eosinophilic infiltration is
considered to be one of the most striking features of asthma (21, 22). In the early stages, the
inflammatory process is often initiated by mast cell degranulation releasing preformed
inflammatory mediators, which is largely restricted to the conducting airways. As the disease
becomes more chronic, the inflammatory infiltration spreads to the smaller airways and in
some instances can transgress into the adjacent alveoli (23).

4

2. Increased mucus secretion: Increased mucus production is one of the hallmarks of
asthma causing obstruction of airways leading to morbidity and mortality. The mucociliary
clearance system is the major removal/filter system in the respiratory tract and is dependent
on the proper composition of its fluid layers (mucus and periciliary). It is comprised of three
major components; sol phase (periciliary fluid), gel phase (mucus) and ciliated epithelium.
Periciliary fluid is produced via active ion exchange by the ciliated epithelial cells and is
non-viscous, composed of water and electrolytes (24). Mucus is viscous and highly elastic
composed of acidic and neutral glycoproteins and flows on top of the periciliary fluid. It
functions to trap inhaled particulates and microbes. The cilia on epithelial cells are embedded
in the periciliary fluid with their tips contacting the mucus layer and beat with a coordinated
wave like rhythm (power forward stroke and slow reverse stroke). This rhythmic beating of
cilia is very important to create a fluid flow in the direction of the pharynx, which allows
elimination of the particulates by swallowing (25). Appropriate balance between sol and gel
phase is essential for effective clearance. In asthma and in other lung diseases (cystic fibrosis
and chronic obstructive pulmonary disease) copious amounts of mucus accumulate which is
more viscous and less elastic resulting in plugging of conducting airways. Airway mucus
which forms a sticky gel layer on the epithelial surface is an important component of innate
host defense (26, 27). In mice, mucus secreting goblet cells (every 5th to 6th epithelial cell)
represent the main source of mucus. In humans, goblet cells are present in the upper regions
up to the 5th tracheobronchial division but under diseased conditions such as asthma and viral
infections they increase in size/number and appear further down causing obstruction by
mucus plugging (28). Also in humans, submucosal tracheobronchial glands composed of
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serous and mucous cells are present in the cartilaginous conducting airways and are a major
source for mucus secretions.

3. Airway remodeling: The airway epithelium acts as an important physical barrier that is
almost impermeable through the formation of tight junctions. However, inhaled allergens
such as house dust mite degrade the tight junctions through their proteolytic enzyme activity,
thus enhancing their penetration into the submucosa in close proximity to dendritic cells
(DCs) and mast cells (29). In addition, mucosal DCs extend their processes between
epithelial cells into the airway lumen and undergo activation upon recognition of
immunogenic components in allergens, leading to a cascade of inflammatory processes.
Therefore, the permeability of the asthmatic epithelium is greatly increased, further resulting
in increased access to inhaled allergens and other irritants (30).
It has been demonstrated extensively that the pro-inflammatory cytokines IL-13, IL1β and TNF-α, as well as stimulants such as histamines, leukotriene LTD4, EGF are
increased during an asthmatic response (31-33) and stimulate intracellular signaling
pathways that lead to proliferation of airway smooth muscle (ASM) cells. Researchers have
also shown the contribution of TGF-β to ASM hypertrophy (34). Bronchial biopsies from
asthmatic individuals with chronic exposure to allergens reveal structural changes with
basement-membrane thickening due to collagen deposition, increased airway smooth muscle
mass due to hypertrophy and hyperplasia, and increased airway mucus secretion (35). These
structural changes are collectively termed airway remodeling and contribute to airway
narrowing and enhanced bronchial constriction seen in asthmatic individuals.

6

4. Bronchoconstriction. Enhanced bronchoconstriction or airway hyperresponsiveness
(AHR) is a clinical feature of asthma. Cysteinyl-leukotrienes (cys-LTs) are a family of proinflammatory lipid mediators, synthesized from arachidonic acid mainly by mast cells and
eosinophils; are potent bronchoconstrictors (36, 37). The family of cys-LTs (LTC4, LTD4,
and LTE4) play a major role in the pathophysiology of asthma and are involved in immediate
and late phase asthmatic responses with increase in the level of cys-LTs in the sputum
correlating with disease severity (38, 39). There are many other bronchoconstrictors involved
in asthma, including histamine, bradykinin, neurokinin A, prostaglandins D and F.
The extent of AHR varies with the degree of severity and is determined by a
methacholine challenge test. Methacholine is an airway stimulant and bronchoconstrictor
which triggers acute reversible airway obstruction causing resistance to airflow. Asthmatic
individuals respond to much lower doses of methacholine as compared to normal individuals
or those with lesser degree of severity.
Inhaled corticosteroids, which are used as the first-line controller medication for the
inflammatory component of asthma, act to diffusely decrease production of inflammatory
mediators and to down-regulate airway smooth muscle responsiveness to bronchocontricting
substances. They do not influence the effects of Cys-LTs directly. Anti-leukotrienes, such as
the cys-LT receptor antagonist, LTRA – montelukast, block the receptor cysLT1Rs and thus
have bronchodilatory as well as anti-inflammatory effects. LTRAs are utilized as second to
third-line controller medications for chronic asthma (40).
Another class of drugs known as β2-adrenergic receptor agonists, such as albuterol,
is widely used in asthma for bronchodilatory effects. β2-adrenergic receptor is present on
7

smooth muscles of bronchi, GI tract, blood vessels, heart etc. The β2-adrenergic receptor
agonists stimulate the receptors which are G-protein coupled receptors, causing smooth
muscle relaxation and hence bronchodilation(41).

iv) Critical Role of Immune Cells in Asthma

Causative or regulatory

1. Innate Immune Cells – Mast cells and Eosinophils. Tissue mast cells and eosinophils are
granulocytic leukocytes thought to have evolved as part of the innate immune response to
parasitic infections. Unfortunately, in the case of allergies and asthma, this defense system
has resulted in a pathologic response to “non-pathologic” substances referred to as allergens,
which on their own will not cause injury.

These types of responses are immunologic and

classified as hypersensitivity reactions (42); in the case of asthma a Type I immediate
hypersensitivity response is elicited. This response occurs within minutes mainly because
the source of the proinflammatory mediators are pre-formed within mast cell granules and
immediately released upon cellular activation.
a.

Mast cell. Tissue mast cells reside in the submucosal areas of the respiratory

tract and in the skin, providing an essential first line of defense against exposure to
environmental pathogens (43). Once an atopic individual (genetically prone to produce
IgE antibodies) has developed IgE to several antigenic epitopes, the IgE binds to low and
high affinity Fcε (CD23 and FcεRI) receptors on tissue resident mast cells, macrophages
and DCs (44, 45). Upon further exposure of the individual to specific allergens, allergen
binds to the specific IgE on the Fcε receptor and ensuing cross-linking of Fcε receptors
bound to IgE takes place, which leads to the activation and degranulation of mast cells.
This event is considered one of the important steps in the pathogenesis of asthma (46,
8

47). FcεR1 and CD23 cross-linking causes degranulation of mast cells resulting in the
release of histamine (vasodilator and bronchoconstrictor), proteoglycans, prostaglandin
D2, leukotrienes (LTC4, LTD4, and LTE4) with bronchoconstricting properties,
eosinophil chemotactic cytokines such as eosinophil chemotactic factor (ECF), RANTES,
IL-5, as well as other Th2 type cytokines, IL-4, IL-5, and IL13; culminating in damaged
airway epithelium (48, 49).
b.

Eosinophils. Eosinophils are granulocytic leukocytes that are thought to have

evolved as part of the innate immune response against parasitic infections (50).
Eosinophils have a central role in the inflammatory networks that are established in an
asthmatic lung. The presence of these innate cells in the bronchoalveolar lavage (BAL)
and lung tissue of asthmatic individuals and in animal models is considered a hallmark of
the disease (51, 52). In response to IL-5, eosinophils traffic from the bone marrow and
tissues to the circulation and further in response to more local chemotaxis factors like
eotaxin and RANTES, migrate closer to the site of tissue injury, the lung. Eosinophils
that traffic to the site of inflammation are further activated by stimuli such as IL-5, GMCSF, IL-13 and IgE, leading to degranulation. Importantly, eosinophils also activate
mast cell release of pro-inflammatory mediators including histamine, eicosanoids and
cytokines (53-55). The final result of mast cell and eosinophil degranulation is damage to
airway architecture and vasculature, injury to epithelial cells, increased mucus secretion
and smooth muscle hypertrophy.
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2. Effector “Proinflammatory” T Cells and B Cells
a.

Effector CD4 T Cells. Lineage classification:

The central role of CD4 T cells in the pathogenesis of asthma was investigated twenty
years ago, with numerous studies reporting the prevalence of high number of CD4 T cells
in asthmatics and their crucial role in cytokine production, airway infiltration and mucus
production (56, 57). CD4 T cells are classified based on their functions into various
subsets of T helper cells namely: Th1, Th2, Th9, Th17 and regulatory T cells (Tregs).
Upon stimulation with appropriate signals and in the presence of IL-2, naïve CD4 T
helper cells called Th0 cells differentiate into Th1 cells and secrete IFN-γ, which is the
master cytokine in a Th1 skewed immune response. Th1 responses are associated with
viral infections, tumor responses and autoimmunity (58, 59). The Th2 immune response
is mediated mainly by the cytokine IL-4, and this type of immune response is crucial for
clearing parasitic infections and for the pathogenesis of allergy and asthma (57, 60).
Recent evidence also implicates the role of the Th9 and Th17 types of CD4 helper T cells
in the development of asthmatic symptoms, specifically airway remodeling and AHR,
respectively (61).
Role in Asthma: During the initiation of the immune response in the lung to an allergen,
“immature” DCs in the submucosa of the lung phagocytize and process
antigens/allergens, to become activated “mature” DCs.

Upon migration to the draining

lymph node of the lung (mediastinal lymph node),they present antigen to T cells, which
in turn leads to the activation and clonal expansion of Th2 cells that secrete the cytokines
IL-4, IL-5, IL-9 and IL-13 (62). These T cells in response to tissue specific chemokines
then migrate to site of injury in the lung tissue. The local Th2 skewed cytokine milieu
10

maintained in lung tissue after exposure to allergen by mast cells, eosinophils, and DCs
also favors Th2 differentiation of naïve T cells in-situ (63-65).
Some individuals are genetically prone to develop Th2 type immunity and this may
explain why some people are more susceptible to developing allergies and asthma than
others. Further studies on prevention of CD4 T cell priming to Th2 during the
sensitization phase may offer better treatment strategies for controlling asthmatic attacks.
Memory T cells play an important role in chronic pulmonary inflammation. After
the attenuation of initial asthmatic symptoms either by treatment with corticosteroids and
bronchodilators or by removal of the causative allergen, a small subset of the CD4 T cells
persists and forms the memory pool. This Ag-experienced population of CD4 T cells is
responsible for a faster response of higher magnitude leading to exacerbated symptoms
upon re-exposure of the same individual with the same class of allergen. This type of
response is commonly seen in chronic asthmatic patients.
Human and mice studies have shown that a Th17 predominant asthmatic response with
neutrophilic infiltration in the lung is commonly seen in many chronic and severe cases of
asthma (61).
b.

Effector CD8 T Cells. Several studies have demonstrated the role of CD8 T

cells in the pathogenesis of asthma, particularly related to airway remodeling with
chronic exposure to allergens. Similar to CD4 T cells, CD8 T cells are also subdivided
into Tc1 and Tc2 populations (66-68). Tc1 type CD8 T cells are activated by IL-2 and
secrete IFN-γ (69), whereas Tc2 cells secrete IL-4 in the presence of IL-2 and IL-4 (70).
Such Tc2 type CD8 T cells have identified in a wide spectrum of diseases such as
asthma, chronic obstructive pulmonary disorder, graft versus host disease and several
11

forms of cancer. CD8 T cells are known to have both pro-inflammatory and antiinflammatory actions and thus have a controversial role in asthma. Tc1 cells are capable
of suppressing IgE production through an IFN-γ, IL-12 and IL-18 mediated mechanism,
which would result in the alleviation of asthma symptoms (71).
Studies in mice have shown that adoptive transfer of Tc1 type CD8 T cells into allergen
(ovalbumin-OVA) sensitized mice, results in inhibition of IgE mediated responses in the
recipient mice upon challenge with OVA via airways (72). On the other hand, studies
have demonstrated that intraperitoneal (I.P.) sensitization followed by aerosol challenge
with OVA in CD8-/- mice resulted in reduced AHR, lung eosinophilia, and decreased IL13 production in the BAL fluid compared to WT mice (73, 74). This study associates
CD8 T cells with a pro-inflammatory role in the pathogenesis of asthma. These findings
suggest that promoting Tc1 type response and suppressing Tc2 type CD8 T cell response
would provide insights into developing alternate therapeutic options for treating asthma.

Effector B cells: Lineage classification
B cells are a major player in the pathogenesis of asthma and are generally considered as
promoters of immune responses. This is due to their ability to produce antibodies specific to self
and non-self antigens and to serve as antigen presenting cells, thus facilitating optimal T cell
responses (75). Hence, they are responsible for eliciting productive humoral immunity against a
variety of bacterial, fungal and viral infections. Human and murine B cells have traditionally
been divided into 2 major subtypes based on their function and phenotypic differences; that is,
B1 cells and B2 cells (76). In mice, B1 cells are characteristically B220lo, IgMhi, IgD+, CD43+,
and CD23lo. B1 cells are further classified based on CD5 expression as CD5+ B1a cells and CD512

B1b cells (77). B1 cells are important source of natural antibodies and secrete higher amounts of
IgM than IgG, and their immunoglobulin receptors show polyspecificity. In comparison to B1
cells, B2 cells are conventional class switching B cells, which produce antibodies of different
isotypes such as IgG, IgE and IgA. In mice B2 cells are phenotypically B220hi, IgMlo, IgD+,
CD43-, and CD23hi (78). B2 cells have much more diverse B cell receptor (BCR) than B1 B
cells. Unlike B1 cells, B2 cells get activated in response to antigen, undergo several rounds of
divisions in the extra-follicular regions or form germinal centers and give rise to memory or
plasma cells in the periphery (79). B2 cells constitute majority of the peripheral B cells found in
lymphoid organs and in circulation (80).
Effector B cells and Asthma:
The level of IgE secreted by B cells is often used to predict the severity of asthma.
Individuals who exhibit higher levels of circulating IgE in the serum are more prone to
developing allergies and asthma than others, and these individuals are considered atopic (81). B
cell activation in the presence of IL-4 and IL-5 is very crucial, along with CD4 T cell help, for
class switching into IgE secreting B cells. Circulating IgE secreted by activated B cells during
the early phase of an allergic reaction binds to its cognate receptors on mast cells and eosinophils
resulting in degranulation and release of various mediators of the allergic response.
Given the multifaceted role of IgE in asthma, targeting IgE antibody in the serum of an
asthmatic individual seems to be a promising therapeutic option. The anti-IgE monoclonal
antibody Omalizumab® has been used successfully for treating individuals with asthma (82, 83).
Depletion of IgE-secreting B cell lineage using depletion antibodies has been reported as a novel
approach to treat allergic airway disease in mice (84). Although studies in B cell deficient mice
demonstrate the development of pulmonary eosinophilia and Th2 differentiation, these mice have
13

attenuated AHR suggesting the major contribution of B cells to the inflammatory cascade in the
disease (85-87).
B cells have several other important pro-inflammatory and anti-inflammatory actions.
Apart from antibody secretion, B cells function as professional APCs by processing the antigen,
in this case allergen, via receptor mediated endocytosis and present the antigenic peptide to Th2
cells on MHC II molecule (88, 89). They can also have a major regulatory role in asthma and
other autoimmune diseases, as discussed in a later part of this thesis. Detailed studies on the
multiple roles of B cells in the development of asthma will yield the discovery of novel therapies
for asthma and other disease.

v) Chemokine Signaling/Leukocyte Recruitment Orchestration or traffic jam

The recruitment of leukocytes into the lung tissue in response to chemotactic attractants
is one of the most crucial steps in the pathogenesis of asthma. Chemokines, or chemotactic
cytokines, are a small family of 8 to 10 kDa sized proteins that are secreted by a variety of
hematopoietic and non-hematopoietic cells during an immune response. Based on the
positioning of the two cysteine residues, chemokines and their receptors are divided into two
main categories namely, C-x-C or C-C. At present, 6 CxC and 10 CC chemokine receptors; 16
CxC and 28 CC ligands have been identified in humans (87). A chemokine concentration
gradient originates at the inflammatory site, which leads to the recruitment of various
inflammatory cells that express the cognate G-protein coupled receptors for the specific
chemokines (87, 90).
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1. Leukocyte trafficking into the lung tissue: An asthmatic response can be considered
to manifest in two distinct phases: early and late phase. In the early phase, local mast
cell activation and release of mediators occurs, leading to acute asthmatic attack in
response to inhaled antigenic stimulus. The early phase response typically resolves,
but after several hours, a more severe late phase reaction occurs (91, 92). Late phase
response involves infiltration of different types of leukocytes into the lung tissue due
to chemokines also released during the early response and to constant exposure to the
stimulus. This response lasts for prolonged periods of time, and the chronic exposure
to allergen results in heightened inflammation and long term damage to airways (93).
The expression of various chemokines in the lung tissue and BAL during the
different stages of asthma has been well established. Airway epithelial cells and
alveolar macrophages are the immediate cellular sources of chemokines upon
exposure to allergen. CCR3 has been identified as an important chemokine receptor
for the recruitment of eosinophils into the lung tissue (94). The two common
chemokines for CCR3 that are found in the BAL fluid of humans and mice are CCL5
and CCL11, and have been shown to be important for infiltration and activation of
eosinophils. Recent studies have indicated the significance of CCL11 in causing
degranulation of these cells and release of mediators such as histamine and
leukotrienes (93).
Thymic stromal lymphopoietin (TSLP) is another critical chemokine for the
initiation of allergic inflammatory responses. TSLP, expressed at high levels by lung
epithelial cells after allergen exposure, is an important chemoattractant for CD4+ T
cells and for Th2 differentiation (95). Studies have shown that human and mouse
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CD11c+ DCs, when treated with TSLP, increase production of the chemokines CCL7
and CCL22 that attract Th2 type CD4+ T cells (96). It has also been well established
that TSLP primed DCs skew towards Th2 differentiation and stimulate CD4+ T cells
to produce IL-4, IL-5, IL-13 and TNF-α (97). In asthmatic patients, lung epithelial
cells and the submucosa harbor greater levels of TSLP mRNA compared to control
subjects and their BAL fluid has higher TSLP protein expression (98).
Studies have demonstrated that LTB4 and the chemokines CCL1, CCL17, and
CCL22 secreted by IgE-stimulated mast cells mediate T cell recruitment in the early
phase of an asthmatic response (99, 100, ). When BAL T cells from control subjects
and asthmatic individuals were compared, the expression of the chemokine receptors
for T cell recruitment CCR5, CXCR3 and CXCR4 on T cells were higher in
asthmatic individuals than controls (101).
Thus the chemokine-receptor signaling axis in lung tissues represents a major
factor for the initiation and progression of asthma. Further detailed studies elucidating
the role of several other chemokines and their receptors have to be established.

2.

Orchestrated trafficking of immune cells in the HLN: Exposure to allergen in the
presence of inflammatory signals such as TSLP, IL-4, IL-5, and IL-13 results in
maturation of DCs that skew towards a Th2 phenotype. These activated DCs migrate
from the lung tissue to mediastinal/hilar lymph nodes (HLN), present antigen to naïve
T cells and activate them to differentiate into Th2 effector cells. These allergen
specific effectors T cells (Teffs) undergo clonal expansion and exit the lymph node to
re-enter circulation to peripheral tissues (102). Most of the Teffs undergo death and
16

only a small population of memory T cells survive. Memory T cells circulate in blood
whence they migrate to peripheral tissues and to lymphoid organs in response to
chemokine gradients. Upon re-exposure to the same allergen in the lung, memory T
cells undergo enhanced activation producing inflammatory Th2 cytokines, thus
leading to the progression of asthma (103). Th2 type CD4+ T cells are also necessary
for providing T cell help to B cells for IgE synthesis, which happens in the lung
mucosa or in the HLN. B cells present cognate antigen to antigen specific T cells via
MHC II - TCR interaction, while T cells provide help via CD40-CD40L and ICOSICOSL interactions. IL-4 and IL-13 secreted by T cells are important for class
switching to IgE, thus leading to production of pathogenic IgE (104). B cell class
switching and affinity maturation are discussed in detail below.

vi) Lymph Nodes and Germinal Centers

Antibody synthesis or not

Secondary lymphoid organs such as the spleen and peripheral lymph nodes are highly
organized structures. The anatomical location of T cells, B cells and antigen presenting cells in
specific compartments of the lymph nodes is essential for productive interactions between these
different cell populations. Localization of different types of cells in specific regions of the lymph
node is governed by the expression of chemokine receptors on the cell surface and their response
to corresponding chemokines (105).
1. Lymph node architecture: The lymph node can be distinguished into two regions,
the cortex and medulla. The cortex is further classified into the T cell zone
(paracortex) and more superficial B cell follicles which comprise primary follicles
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and, after antigen exposure, germinal centers. Circulating lymphocytes enter the
lymph node through high endothelial venules (HEV) into the T cell zone, where T
cells reside and interact with DCs. B cell follicles are the sites of initiation of a
humoral immune response. The medulla consists of many lymph draining sinuses
where plasma cells, macrophages and memory T cells are present. Free antigen
and/or antigen loaded DCs from peripheral sites of antigen introduction traffic
into the lymph nodes via afferent lymphatics. Lymphocytes exit lymph nodes
and re-enter the circulation through efferent lymphatics (105, 106). Homing of T
cells, DCs and B cells into specific compartments is governed by chemokine
gradients and expression of chemokine receptors on the cell surface, Figure 1
(107).

2. T cell zone: Naïve and memory T cells enter the lymph node to sample antigens
presented by DCs and further elicit an efficient immune response. Reticular
fibroblast cells (which form the cellular framework of T cell zones) and HEVs
secrete the chemokines CCL19 and CCL21, which enable trafficking into T cell
zones. CCR7 (the receptor for CCL19 and CCL21) is expressed by naïve and
memory T cells and is also up-regulated on activated DCs (108, 109).

3. B cell follicles and germinal center (GC) formation: Follicular dendritic cells
(FDCs), which are present in lymph follicles, are the main producers of the B cell
chemoattractant- CXCL13. One of the other key functions of FDCs is to present
antigen via immune complexes to GC B cells. Most B cells (all naïve and most
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activated B cells) express CXCR5 on their surface, which binds CXCL13
expressed in the follicles, and thus traffic to these regions of secondary lymphoid
tissues (107).
Following antigen exposure and antigen-receptor binding, B cells up-regulate
CCR7 and have greater responsiveness to CCL19 and CCL21 than CXCL13 and
thus, migrate to the boundary between T and B cell zone or T cell/B cell border
(110). A sub-population of CD4+ T cells that are activated by DCs in response to
the same antigen up-regulate CXCR5 on their surface and down regulate CCR7.
Thus these cells are responsive to CXCL13 and migrate to the T cell/ B cell
border where they interact with B cells that present the cognate antigen. Here, T
cells provide T cell help to the B cells, which is necessary for T dependent
antibody production. These activated B cells become antibody secreting
plasmablasts and can further undergo class switching to various specific antibody
isotypes (i.e., IgG, IgA, IgE) depending on the cytokine milieu. These cells that
down-regulate CCR7 and CXCR5 are called extrafollicular plasmablasts and are
present in the medulla or exit the lymph node via efferent lymph vessels (111).
A small fraction of B cells that are activated at the T cell – B cell border,
retain the expression of CXCR5 and migrate to the follicles to form the germinal
center. Small populations of T cells which are called follicular helper T cells
(Tfh cells) also traffic to the GC. Mature GC has been described to consist of two
distinct poles- dark zone, proximal to T cell zone and light zone- distal to the
T cell zone (112). The dark zone contains rapidly proliferating centroblasts which
undergo somatic hypermutation introducing mutations in the antigen binding
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region of the antibody. Centroblasts up-regulate CXCR4, which binds CXCL12
present in the dark zone of a GC. After several rounds of proliferation, the
centroblasts down regulate CXCR4 and become non-diving centrocytes. The
centrocytes migrate to the light zone via CXCR5-CXCL13 interaction. Tfh cells
and FDCs are also present in light zone and the centrocytes undergo selection in
this region. FDCs sequester antigen and present to the centrocytes via immune
complexes and the centrocytes that fail to bind antigen or that do not obtain T cell
help from Tfh cells undergo apoptosis. In contrast, the centrocytes that
successfully bind antigen presented by FDCs and receive help from Tfh cells
survive and exit the GC as long-lived plasma cells secreting copious amounts of
antibody or as memory B cells (112, 113).
Orchestrated trafficking of immune cells to their respective compartments
in the lymph node and to the tissue by the expression of appropriate chemokine
receptors on their surface is extremely important for eliciting productive cellular
and humoral immune responses. Detailed studies on lymphocyte trafficking in the
HLN are required to better understand the cellular interactions and localization
during initiation and progression of asthma/allergic airway disease.

B) Murine Model of Asthma- Allergic Airway Disease

Of mice and men

Animal models of asthma are valuable tools to study the various mechanisms and
pathways involved in the pathogenesis of the disease. Some of the advantages of these models
are: relatively low cost for conducting experiments, availability of inbred and transgenic strains,
and abundant tools and reagents for testing multiple parameters.
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Antigen-induced allergic airway disease (AAD) in animal models is a consequence of
Th2 driven inflammation against non-pathogenic inhaled antigen and presents with the classical
features of asthma such as airway inflammation, mucus hypersecretion and IgE production.
Despite the advantages, a basic difference between human asthma and the animal model is that in
most studies the antigen that is used is chicken ovalbumin (OVA), which does not elicit an
inflammatory response on its own. Hence, a method of forced sensitization is commonly
employed where the adjuvant alum (aluminum hydroxide) and OVA are intra-peritoneally (i.p.)
injected. Sensitization with alum via this route results in activation of a Th2 immune response
upon subsequent challenge with OVA, which is administered by aerosols, intra-nasal (i.n.) or
intra-tracheal (i.t.) routes. The major drawbacks of this model are sensitization of the Ag with
alum and the model antigen being extremely simple in terms of its chemical and biological
properties, unlike human relevant allergens such as house dust mite which is very complex and
has its own adjuvant properties.
Aerosol route of delivery is most commonly employed where the animals breathe in the
antigen similar to human encounter of allergen. In this method, the mice are immobilized in
plastic restrainers and plugged into an aerosol machine. The machine has an in-built nebulizer
which aerosolizes and delivers OVA at a controlled rate to the mice.

i) Ovalbumin Induced- AAD model
In our lab we employ a model of AAD that closely represents the events occurring in
naturally acquired human asthma with sensitization, acute and chronic phases of the disease,
Figure 2.
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Sensitization phase: As mentioned above, sensitization is achieved by giving mice 3
weekly i.p. injections of OVA and alum. This protocol is followed to achieve maximum boost
during sensitization. Significant levels of OVA specific IgE develop in the serum after
sensitization. Mice that are sensitized to OVA in this manner retain their ability to respond to
OVA throughout their lifespan.

Acute phase- AAD: One week after the last i.p. injection, the mice are subjected to 1%
OVA aerosol exposure daily in order to elicit a robust Th2 response. The pathophysiology of
allergic airway disease in mice closely resembles that of human asthma. The classic clinical
features of asthma begin to manifest in these mice around day 3 until day 14 of aerosol
challenge, with peak disease characteristics on day 7 which we term AAD. Typical
characteristics of an AAD response include infiltration of CD4 T cells, eosinophils, B cells and
CD8 T cells in the BAL and lung tissue. The Th2 cytokines IL-4, IL-5 and IL-13 are also
increased in the BAL fluid. We observe the other hallmark characteristics of asthma, such as
increased mucus in the airway, hyper-responsiveness to methacholine and smooth muscle
hypertrophy (114).
Disease development and severity in the animal models is critically dependent on CD4 T
cells as mice deficient for CD4 T cells (CD4-/- mice) do not develop AAD (115). When Rag-/mice (deficient for T cells and B cells) are transferred with CD4 T cells alone prior to
sensitization, they develop airway inflammation and hyper-reactivity (116). However, B cell
deficient mice (µMT and JhD-/- mice) develop AAD despite the absence of B cells (117) . The
valuable information obtained from these studies is extremely useful for developing
immunotherapy strategies for asthma.
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Laboratory techniques employed for assessment of disease: Commonly employed
techniques in the lab are histology, flow cytometry, measurement of sensitivity to methacholine
(AHR) and confocal microscopy. Histology: Increased airway infiltration with lymphocytes and
eosinophils at AAD compared to naïve or sensitized stages can be visualized by staining lung
tissue sections with H&E, where the nuclei are stained in blue. Majority of the inflammation at
AAD is found in the perivascular and peribronchial regions. Increased mucus and smooth muscle
hypertrophy/collagen deposition are assessed using PAS and trichrome staining, respectively.
Confocal microscopy: We also obtain useful functional and phenotypic information about
particular cell types such as CD4, CD8 T cells or B cells etc., in the lung tissue and lymphoid
organs by using appropriate cell surface and intracellular markers and analyzing using a confocal
microscope. Flow cytometry: Increased airway infiltration at AAD in the pulmonary
compartment (BAL, lung tissue, HLN) as compared to the systemic tissues such as spleen and
inguinal lymph node (ILN) is quantified using this technique. We obtain quantitative data on the
functional and phenotypic changes of the various subsets of cells during different stages of the
model. The common features observed at AAD following aerosol challenge are: expansion of
Th2 type CD4+ T cells (expressing T1/ST2), increased expression of MHC II expression on lung
DCs and B cells, up-regulation of activation markers such as CD25 and CD44 on CD4 T cells.
AHR measurement: Physiological measurements of lung function at different stages of the model
is carried out by measuring lung resistance to methacholine using whole body unrestrained
plethsymography. Mice at AAD have greater lung resistance at a lower concentration of
methacholine compared to naïve or sensitized mice. Detailed description of the various
techniques is discussed in the material and methods section.
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Chronic phase- Local inhalational tolerance (LIT): One of the remarkable features of our
model is its biphasic nature, where continuous aerosol challenge for a period of 42 days results in
the spontaneous resolution of the disease. This is a very important clinical feature as it mimics
seasonal allergies and particularly in the case of continuous exposure to bee-stings in humans,
where the symptoms wane away with chronic exposure to allergen. We termed this phase of the
model as LIT as the mice become locally tolerant to OVA with absence in airway inflammation
and eosinophilia, airway hyper-responsiveness and mucus production in the local lung
compartments; however, the serum levels of IgE remain elevated, and footpad OVA challenge of
mice at LIT results in footpad swelling (118). Continuous Ag exposure is required for the
establishment of LIT, as a break in the exposure to OVA and re-exposure results in reappearance
of airway inflammation and other features of AAD (119). Understanding the mechanisms
involved in the establishment of LIT will provide valuable information that can be used for
devising treatment options to induce tolerance towards allergens in asthmatic individuals.
Our lab has dedicated more than a decade to studying the features and mechanisms of
LIT. Some important features observed are the clearance of airway inflammation at the
perivascular and peribronchial sites in the lung tissues similar to mice at naïve or sensitized
stages. We also observed absence of eosinophils and Th2 cyokines in the BAL of mice at LIT
and resolution of AHR measured by sensitivity to methacholine. Another important feature of
LIT is the accumulation of regulatory T cell and B cells in the lung compartments, which play a
crucial role in the establishment of tolerance as is discussed in detail in later sections (119). We
have also implicated the role of cytokines in the induction of tolerance, especially the role
immuno-suppresive cytokines- IL-10 and TGF-β. We have demonstrated that mice deficient for
IL-10 develop LIT normally, which suggests that in our model, tolerance induction is not
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mediated by IL-10 dependent pathways. Interestingly we have shown that TGF-β mRNA is upregulated in lung tissue at LIT (120). We have also demonstrated a TGF-β dependent mechanism
for induction of tolerance by B cells (85), which is also discussed in depth in later sections. It is
possible that there are multiple mechanisms for development of LIT which are currently
investigated in our laboratory and is also the focus of this thesis.

Other models of airway tolerance induction: There are other models of inhalational
tolerance previously described, which employ a different Ag exposure regimen or a different
route of Ag administration. Some models study the onset of tolerance by exposure to inhaled
OVA or administration of Ag with intratracheal administration without adjuvant prior to
sensitization, whereas others employ feeding of naïve mice with OVA followed by subsequent
sensitization with adjuvant and OVA challenge (121). The mechanisms of development of
tolerance in these models vary from generation of T cell anergy (122), induction of tolerogenic
DCs (123) and so forth. Although these models are very important for investigations, they do not
follow the natural course of development of exaggerated Th2 response before tolerance induction
as our model, and they result in systemic tolerance rather than LIT.

C) Establishment of Immune Tolerance and Role of Regulatory Cells Putting out the fire

Immune Regulation in Asthma and Other Diseases
Balance between positive and negative control of the immune system (in other
words, balance between pro- and anti- inflammatory responses) is critical to maintain immune
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homeostatis. Regulatory T cells and B cells, tolerogenic DCs and macrophages have an
indispensable role in suppressing chronic excessive inflammation that is deleterious to the host
and in maintaining unresponsiveness to self-antigen. This balance is mediated by stimulatory and
inhibitory signals from appropriate effector or regulatory cells.
When the host encounters a pathogen, the activation of innate immune system followed
by activation and clonal expansion of antigen-specific effectors T and B cells, production of proinflammatory cytokines etc. takes place. After clearance of the pathogen, the on-going immune
response should to be terminated in order to prevent chronic damaging inflammation. Some
molecules that play a critical role in host immune regulation are receptors such as PD-1 and
CTLA-4, which act as a check point for unwanted damaging inflammation (124, 125). In the
case of autoimmunity, discrimination between self and non-self antigens fails and leads to the
destruction of host cells and tissues. This situation is common in individuals with inherent
problems in immune regulation, for example, in IPEX syndrome where mutation in Foxp3 gene
(master transcription factor of Tregs) results in dysregulated functions of Tregs and the body’s
own immune system attacks the body’s own tissues (126).
In asthma, the host elicits a pronounced Th2 response against harmless foreign antigen
resulting in damage to host tissues such as the lung. Thus, understanding immune regulation in
asthma and studying mechanisms that induce tolerance towards the harmless allergen is of
paramount importance. In our biphasic model, the mice spontaneously develop tolerance to
OVA, which thus serves as propitious platform to study the various cell types and mechanisms
involved in the induction of tolerance. These studies are currently undertaken in the lab with the
hope of translating the findings to clinical treatments for improving the conditions of asthmatic
individuals.
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i) Role Regulatory T cell in Asthma and Autoimmunity
There is a considerably large number of scientific studies in the literature that have
proven a critical role for CD4+ Foxp3+ T cells in the attenuation of allergy and asthma. Tregs can
be broadly classified into Foxp3 expressing Tregs whose characteristic function is production of
the cytokine TGF-β and Tr1 cells which predominantly produce IL-10. Both these subsets are
CD4+. The Foxp3 expressing Tregs can be generated in the thymus (natural or nTregs) or can be
induced from peripheral CD4+ Th cells (induced or iTregs).
Mechanism of action: There are multiple mechanisms identified by which Tregs exhibit
their suppressive functions. Some of them are production of anti-inflammatory cytokines such as
IL-10 and TGF-β that inhibit proliferation of effector T cells, induction of Teff apoptosis and
inhibition of APC activity (127); Tregs express the inhibitory receptor CTLA-4, which competes
for CD80/CD86 binding on APCs and results in down regulated expression of these molecules
and decreased co-stimulation.

Tregs in autoimmune diseases: Tregs play an indispensable role in a multitude of
autoimmune diseases including multiple sclerosis (MS) and systemic lupus erythematosus
(SLE). SLE is an autoimmune condition with dysregulated autoreactive B cells, which results in
production of auto-antibodies against self nuclear antigens and deposition of immune complexes
leading to uncontrolled tissue inflammation (128). Studies in individuals with SLE have shown
that SLE patients have impaired Treg production or maintenance, resulting in a low Treg
frequency. The low Treg frequency correlates with increased disease severity and high autoantibody titers (129). Multiple sclerosis is a complex genetic disorder with auto-reactive T cells
and B cells that attack myelin antigens. Numerous studies in MS have shown that Treg defects
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are a major factor for lack of control of disease. It has been demonstrated that Tregs from MS
patients, when compared to control subjects, have impaired suppressive functions in vitro (130).
These examples show that Tregs are an important arm of immune regulation that is critical for
controlling immune responses of various cell types.

Role of Tregs in asthma: We have demonstrated that Tregs accumulate in the HLN, lung
tissue and BAL fluid at LIT and that adoptive transfer of Tregs into sensitized mice suppresses
development of AAD upon OVA challenge. Recent studies in DEREG mice, in which Tregs can
be selectively depleted by diphtheria toxin injection (depletion of regulatory T cells- DEREG),
show that depletion of Tregs during the sensitization phase leads to exacerbated symptoms of
allergic airway disease. This study shows that Tregs are not only important for induction of
tolerance but also have an important role in regulating immune responses against allergen as
early as sensitization (131).

ii) Role Regulatory B cells in Asthma and Other Autoimmune Diseases

Breg phenotype and mechanism of action:
B cells are traditionally considered to be pro-inflammatory and positive regulators of
immune responses. However, recent advances in B cell biology have challenged the old dogma
that regarded antibody production as the only important function of B cells. Certain types of B
cells also act as negative regulators of an immune response by producing anti-inflammatory
cytokines or through direct contact with B cells and T cells. B cell mediated immune suppression
was first described in 1974, when the ability of B cells to suppress delayed-type hypersensitivity
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reaction was demonstrated (132, 133). However, the concept that B cells can exert regulatory
functions has not been fully appreciated until the last decade, when their modulatory effects have
been demonstrated in a variety of murine models of chronic inflammation, including
inflammatory bowel disease, rheumatoid arthritis, experimental autoimmune encephalomyelitis
(EAE), and asthma (134).
Similar to regulatory T (Treg) cells, Bregs elicit immune regulation by various
mechanisms. Bregs may exert their effects on T-cell responses indirectly, by inhibiting the innate
immune system. Conditioning of dendritic cells (DCs) by CD5+, CD1dhi B cells results in less T
cell proliferation compared to conditioning by non-regulatory B cells (135). In addition, cocultivation with Breg cells inhibits DC maturation, antigen presentation, and expression of the
co-stimulatory molecules CD80 and CD86 via IL-10 dependent (136) and IL-10 independent
mechanisms (137). Antigen presentation by immature DCs induces T-cell tolerance rather than T
cell activation and pro-inflammatory cytokine production. Breg cells also can induce anergy in
CD8+ T cells directly, by functioning as antigen-presenting cells with impaired IL-2 production
(138). Breg cells also express a number of signaling molecules that may play key roles in their
suppressive actions. Breg expression of glucocorticoid-induced TNF receptor ligand (GITRL)
may play an essential role in homeostasis by maintaining natural Treg cell (nTreg) numbers
above a threshold required for the prevention of autoimmunity. Bregs also modulate the immune
response through production of anti-inflammatory cytokines and expression of inhibitory
molecules.
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Role of Bregs in autoimmune diseases and allergies
Perhaps the best described Breg cell is the IL-10 secreting B10 cell (139). B10 cells
appear to have a B1a origin and are CD5+ and CD1dhi. In mice, B10 cells have been shown to
inhibit the progression of inflammation and/or hasten the recovery from inflammatory bowel
disease (140), experimental autoimmune encephalomyelitis, systemic lupus erythematosis (141144), and rheumatoid arthritis (145). A comparable IL-10-competent B10 cell subset has been
identified in human blood within the CD24hi, CD27+ and/or CD24hi, CD38hi B-cell
subpopulations (146, 147).
In addition to these IL-10-producing B10 cells, a Breg subset that is capable of producing
TGF- after in vitro stimulation with LPS has been identified. Transfer of such TGF-producing
B cells into B-cell deficient NOD mice suppresses the development of diabetes in the recipient
mice by inducing apoptosis of the effector T cells (148). TGF-producing Breg cells may also
participate in the induction of low-dose oral tolerance (149, 150) and in the inhibition of allergic
airway disease (151). A human Breg cell characterized as CD25hi, CD27hi, CD86hi, CD1dhi, IL10hi, and TGF-hi is capable of enhancing Foxp3 and CTLA-4 expression in Treg cells via a
mechanism dependent on direct contact between Breg and Treg cells and on TGF- but not IL10 (152). In addition, both IL-10 producing CD19+CD5+ B cells (B-10 cells) and TGFβproducing CD19+CD5+ B cells have been shown to regulate cow’s milk allergic responses in
human subjects (153, 154).
In the murine EAE model, Breg expression of GITRL, but not IL-10, was required for
proliferation of Treg cell and EAE recovery (155). Another mechanism of suppression by Bregs
is killing CD4+ T cells by Fas/FasL dependent mechanisms. In non-obese diabetic (NOD) mice,
the number of FasL-expressing splenic B cells inversely correlates with the severity of diabetes.
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FasL-expressing B cells mediate immune tolerance in a skin graft model (156) and in cockroach
antigen-induced murine asthma (155). This FasL-dependent apoptotic function has been
attributed to CD5-expressing B cell subsets. Between 50-70% of mouse peritoneal CD5+ B cells
also express the programmed death-1 ligand PL-L2 (156). PL-L2 has been implicated in mucosal
homeostasis and the modulation of oral tolerance and asthma (157), but the potential regulatory
role of these PL-L2-expressing CCD5+ B cells remains to be determined. Lastly, both IL-10expressing (158, 159) and TGF--expressing Breg cells also demonstrate high expression of
CD1d. CD1d is required for the presentation of phospholipid and glycolipid antigens to NKT
cells, and CD1dhi B cells have been shown to promote immune tolerance through activation of
NKT cells in different mouse models (160, 161), suggesting a potential regulatory mechanism
involving Breg and iNKT cell interaction.
Thus, as with Tregs, it is likely that several populations of Bregs exist, and that different
subsets may be preferentially generated based on the types of stimuli, local cytokine
environment, and anatomical sites of antigen exposure. The origins of these Bregs and how they
develop are just beginning to be elucidated. More work towards understanding the mechanism of
regulation and phenotypic characteristics of Bregs in different settings is highly important.

Regulatory B cells and asthma:
Bregs have a significant role in the regulation of asthma . Our lab and many others have
shown the important role of Bregs in induction of tolerance in murine model of allergic airway
disease (85). We have shown that B cells from the HLN of LIT mice, when adoptively into
sensitized mice, suppress the development of AAD following subsequent OVA aerosol
challenge. We have also shown that adoptive transfer of these B cells into sensitized recipients
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increases the number of CD4+ CD25+ Foxp3+ Tregs in the BAL. More interestingly, the Bregs in
our model convert naïve CD4+ Foxp3- T cells into Foxp3+ Tregs via a TGF-β dependent
mechanism. One notable finding in our studies is that these B cells express TGF-β (LAP+ B
cells). In contrast to HLN B cells, we also reported that B cells from AAD HLN or AAD/LIT
spleen did not induce Treg conversion and were incapable of suppressing disease development.
Hence we demonstrated in our biphasic OVA induced AAD model, that B cells from LIT mice,
specifically from the HLN, have a regulatory role and are sufficient for inducing tolerance (85).
Another very interesting study showed that mice with helminth infection were protected from
OVA-induced airway hyperresponsiveness by inducing IL-10 production from splenic B cells,
and the tolerance to OVA in these mice was independent of TGF-β levels (162, 163).
There are several studies that looked at regulatory B cell population in humans, and one
group reported that when CD19+CD24hiCD38hi B cells were activated with anti-CD40 Ab, they
suppressed the differentiation of Th1 cells. This was mediated by IL-10 production and
CD80/CD86 stimulation, but not TGF-β. CD19+CD24hiCD38hi B cells that were isolated from
PBMCs of SLE patients were unresponsive to anti-CD40 stimulation, with less production of IL10 lacking suppressive function (164). Thus unlike murine Bregs, human Bregs mediate
suppression only partially via IL-10 and express different surface markers (164). Despite these
differences, human and murine Bregs share functional similarities and more work understanding
the mechanism of regulation and phenotypic characteristics of Bregs in different settings is
highly important.
The majority of my thesis work is dedicated to characterizing the phenotype of the Bregs
in our AAD model and understanding the trafficking and interactions between the regulatory
cells, as will be discussed in detail in the later chapters. The goals of these studies are to further
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elucidate the mechanisms of LIT and hopefully provide insights into ways of switching off
established human asthma.

D) Hypothesis

Previous studies in our laboratory have defined a regulatory role for B cells isolated from
the HLN of mice at LIT. Adoptive transfer of these HLN B cells suppressed the development of
AAD in OVA-sensitized mice that were subjected to Ag challenge. This inhibitory effect was
associated with an increase in Foxp3+ Tregs in the lung tissue and BAL of recipient mice. The
regulatory HLN B cells (Bregs) also converted Foxp3- naive T effectors to Foxp3+ Tregs in-vitro
(85).
We also identified a subset of CD5+ B cells that remained elevated in the HLN of mice at
LIT. We demonstrated using adoptive transfer experiments that these CD5+ B cells were capable
of suppressing AAD as compared to LIT HLN CD5- B cells. Further, these CD5+ Bregs isolated
from LIT HLNs converted naïve T effectors to Tregs in-vitro, whereas CD5- B cells from HLN
of LIT mice were not able to induce Treg conversion (151).
Lymphoid organs (spleen and lymph nodes) are highly organized structures in which the
anatomical location and trafficking of T cells, B cells and antigen presenting cells in specific
compartments within the lymphoid organs are essential for productive interactions between these
different cell populations (105, 165, 166). Localization of different types of cells in specific
regions of the lymph node is governed by the expression of chemokine receptors on the cell
surface and their response to specific chemokines. Hence, we decided to investigate the in-vivo
induction of regulatory T cells by Bregs within the HLN, by examining the trafficking and
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localization of regulatory and non-regulatory subsets of T and B cells at AAD and LIT via
chemokine receptor expression on cell populations and confocal imaging of the HLN.

We propose that the key events for development of tolerance in the murine model of
OVA - induced AAD occur in the HLN. We hypothesize that the conversion of T effector
cells (CD4+ Foxp3-) to Foxp3+ regulatory T cells occurs in the B cell follicles of the HLN and
is mediated by regulatory B cells. The orchestrated trafficking of T and B cells within the B
cell follicles of HLN, which is crucial to the co-localization of these cells, is directed by the
expression of the specific chemokine receptors - CXCR4 and CXCR5. We will also investigate
the requirement of antigen specificity for the development of Bregs during induction of tolerance
in our model.
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Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN
showing B cell follicles and T cell areas. 20 µm thick. Image of magnification x10.
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Figure 2. Murine Model of Allergic Airway Diease
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CHAPTER 2
MATERIALS AND METHODS

Mice: Female C57BL/6J and HEL transgenic mice (C57BL/6-Tg(IghelMD4)4Ccg/J mice) were
obtained from The Jackson Laboratory (Bar Harbor, ME). Animals were housed in the animal
facility at the University of Connecticut Health Center and were treated in accordance with
institutional and Office of Laboratory Animal Welfare guidelines. All experimental procedures
were approved by the Center for Laboratory Animal Care, University of Connecticut Health
Center.

OVA model for induction of Allergic Airway Disease and Local Inhalational Tolerance: Mice
were immunized with 3 weekly intraperitoneal (I.P.) injections of 25 g OVA (grade V, SigmaAldrich, St. Louis, MO) and 2 mg alum (aluminum hydroxide) dissolved in 0.5 ml saline
solution. One week after the last immunization, the mice are exposed to 1% aerosolized OVA in
physiological saline, one hour/day for either 7 days (AAD) or 42 days (LIT), with an estimated
inhaled daily dose of 30-40 g/mouse. BANG nebulizer (CH Technologies, Westwood, NJ) was
used to generate OVA aerosols into a 7.6L nose-only inhalational chamber attached with
individual mouse-restraint tubes. Mice were sacrificed twenty four hours after the final OVA
aerosol exposure using ketamine/xylazine overdose and subsequent exsanguination.

Bronchoalveolar lavage (BAL)/tissue analysis: At sacrifice, BAL fluid, HLN, ILN, MLN and
spleens were harvested and processed for the isolation and enumeration of leukocytes. For
collection of BAL, lungs were lavaged in situ with five 1.0 ml aliquots of sterile saline. Lymph
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nodes and spleens were harvested and mechanically disrupted into single-cell suspensions, with
lysis of splenic erythrocytes by TAC solution (9 parts 0.83% w/v NH4Cl; 1 part 2.57% w/v Tris,
pH 7.0). For all tissue samples, total nucleated cell counts were obtained using a hemocytometer
with nigrosin dye exclusion as a measure of viability.

Antibodies and immunofluorescence reagents: The following monoclonal antibodies, either
conjugated with corresponding fluorochrome or unlabeled, were purchased from BD Pharmingen
(San Diego, CA) and eBiosciences (San Diego, CA): CD3 (145-2C11), CD4 (RM4-5), CD5 (537.3), CD8 (53-6.72), CD19 (1D3), CD25 (PC61), B220 (RA3-6B2), CXCR4 (2B11), CXCR5
(2G8), Foxp3 (FJR-16s), IL-10 (JES5-16E3), IgD (11-26), and IgM (11/41). APC
(allophycocyanin) labeled H-2Kb tetramers containing the OVA-derived peptide SIINFEKL
were generously provided by Dr. Leo Lefrancois (University of Connecticut Health Center). In
addition, PE labeled anti-CD4 and anti-CD8 were purchased from Coulter Immunology
(Marietta, GA). An anti-latency associated protein (LAP) of TGF- was purchased from R & D
Systems (Minneapolis, MN) and used to detect TGF- bound to cells. Pan-specific TGF-β
neutralizing antibody for in-vitro cytokine blockade assays was purchased from R&D systems
(Minneapolis, MN).

Flow cytometry: Isolated lymphocytes were re-suspended in PBS containing 0.2% BSA and
0.1% NaN3 at a concentration of 1 x 105 to 1 x 106 white blood cells/ml, and 100 µl of the cells
were incubated with 100 µl of properly diluted mAb at 4o C for 30 min. For the identification of
Foxp3+ Treg cells, cells stained with anti-CD3, anti-CD4, and anti-CD25 were permeabilized
using fixation/ permeabilization buffer, following the manufacturer’s protocol, and stained using
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anti-Foxp3-allophycocyanin (FJK-16s) with corresponding isotype controls (eBioscience, San
Diego, CA). For OVA-tetramer staining, APC conjugated tetramer along with other surface
markers were stained for one hour at room temperature. After staining, the cells were washed
twice with PBS containing 0.2% BSA and 0.1% NaN3 solution, and relative fluorescence
intensities were measured on a 4-decade log scale by flow-cytometric analysis using a
FACSCalibur or LSR II (Becton-Dickinson, San Diego, CA). For identification of CXCR4 and
CXCR5 positive cells, cells were stained, incubated at 37o C for 45 minutes, washed in the
above PBS solution, and samples were run on Becton Dickinson LSR II.

For intracellular IL-10 staining, 1 x 106 cells from the Spleen or HLN were plated in a 96-well
plate and treated with BD Golgi Plug® (BD Pharmigen). Cells were stimulated with phorbol 12myristate 13-acetate (PMA) (50 ng/ml; Sigma-Aldrich, Inc.) plus ionomycin (1 μg/ml; SigmaAldrich, Inc.) or left unstimulated for 5 hours at 37°C (167). Cells were then stained for surface
cell markers, treated with Cytofix/perm buffer (BD Pharmigen), and followed by intracellular
cytokine staining with α-IL-10 at 4oC. After staining all samples were run on LSR II and
analyzed with FlowJo, Tree Star Inc., software.
Mice at the various stages were sacrificed on different days and hence the gating strategy was
kept consistent for all tissues at a particular stage. This is shown by different sized quadrants in
the dot plots in figures 1, 5, 6. Selective representative dot plots are presented in each figure.

Confocal Microscopy: HLN and MLN tissues were cryopreserved in OCT for frozen sectioning
(168). Sections of thickness 20 µm were fixed in acetone or glutaraldehyde, washed in ice cold
PBS, and stained for 60 minutes at room temperature with a combination of fluorescently
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conjugated Abs (anti-B220, anti-CD4, anti-Foxp3) in 2% normal goat serum and 2% FCS/PBS
solution. For consistency, the middle sections from each node were used for staining. To detect
Foxp3 positive cells, the sections were prepared and permeabilized using fixation/
permeabilization buffer according to instructions in the Foxp3 staining kit (eBiosciences, CA).
The sections were then Fc blocked (anti CD16/CD32), stained with Foxp3 overnight at 4o C,
washed, mounted and analyzed by confocal microscopy. The images were processed using
Imaris Software.

For quantification of B220+ B cells and Foxp3+ Tregs, the spots tool in Imaris suite was used. B
cell zones were selected using boxes along the entire area of B220+ cell clusters and T cell zones
were selected boxes along the entire area based on the distribution of CD4+ cells. The T-B border
of 100µm thickness (50µm into the B cell zone and 50µm into the T cell zone) was selected
using approximately four boxes of appropriate length and width along the border of B cell zone.
The four boxes represent the T-B cell border for one follicular image. For every mouse, 3-4 such
follicular areas were imaged, and there were 2 mice per group. B220+ cells (green) and Foxp3+
cells (red) were enhanced, and the spots were counted to obtain the total number of each cell
population. The ratios were then calculated from these numbers. To calculate the density values,
X, Y and Z (1.5µm) dimensions were obtained from regions selected based on distribution of T
cell and B cells. The density was calculated using the formula = number of Tregs in a specific
compartment/XxYx1.5 of that compartment, with units = µm-3

Treg cell induction assay: Freshly isolated CD4+CD25– Teff cells were obtained from spleens of
Naïve mice using magnetic bead isolation (Miltenyi Biotech), with >95% purity. These Teff cells
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(1 x 106) were cocultured for 5 days with viable irradiated (2600 Rad) CD19+ B cells (in the case
of HEL mice) or CD19+ CD5+ or CD5– B cells from HLNs or spleens of LIT mice (1 x 106;
isolated as above), soluble anti-CD3 (1 g/ml), and anti-CD28 (1 g/ml). For in-vitro cytokine
blockade, similar assays were performed with or without pan-specific TGF- (20µg/ml). The
cultures were in RPMI 1640 supplemented with 10% FCS and 50 M 2-ME in 24-well plates.
After 5 days in culture, the cells were harvested from the wells, and the intracellular expression
of Foxp3 was assessed on gated CD4+ T cells. All studies were performed in triplicate.

B cell isolation and adoptive transfers: B cells from HLNs and spleens of LIT mice were
positively selected using a mouse CD19+ isolation kit (Miltenyi Biotech, Auburn, CA). The
CD19+ cells were then separated by immunofluorescent labeling and subsequent isolation
utilizing a FACS-Vantage sorter into CD5– and CD5+ subpopulations. Purified B cell
subpopulations (0.2 x 106 CD19+CD5+ or 1.0 x 106 CD19+CD5– cells) were injected by tail vein
into sensitized animals 2 days prior to 7 days of OVA aerosol exposures. Different numbers of
CD19+CD5+ and CD19+CD5– cells were chosen for transfer to represent their relative
proportions in the whole LN adoptive transfer studies (85).

Statistical analysis: Data were expressed as mean ± standard error of mean values. Statistical
comparisons between group means were made with ANOVA followed by Fisher’s protected
least significant difference test between possible pair-wise combinations of means (StatView 4.5;
Abacus Concepts, Berkeley, CA or JMP7; SAS Institute, Cary, NC). In all comparisons, P < 0.05
was used to determine statistical significance.
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CHAPTER 3

REGULATORY B CELLS FROM HILAR LYMPH NODES OF TOLERANT MICE
IN A MURINE MODEL OF ASTHMA ARE CD5+, EXPRESS TGF- AND
CO-LOCALIZE WITH CD4+ FOXP3+ T CELLS

INTRODUCTION
Research over the last three decades has provided overwhelming evidence that asthma is
an inflammatory disease of the airways orchestrated by T lymphocytes (169, 170). Activation of
Th2 effector lymphocytes (Teff) causes elaboration of cytokines such as IL-4, IL-5, and IL-13,
which in turn results in eosinophil activation and IgE production intrinsic to allergic
inflammation (171, 172). The identification of regulatory T lymphocytes (Tregs) that can
modulate Teff function has led to intensive research on their role in allergic asthma (173, 174). B
lymphocytes have traditionally been viewed as target cells for Th2 cytokines, with IL-4 and IL13 responsible for the initiation and maintenance of B cell IgE production (175). However,
emerging evidence suggests that there are also regulatory types of B cells (Bregs), which are
specifically induced under inflammatory conditions (176-178) and are capable of suppressing
inflammation, enhancing recovery, or inducing tolerance (179). Such Bregs have been implicated
in the development of nasal tolerance to aeroallergens (180). Like Tregs, Bregs may comprise
several subpopulations that exhibit different mechanisms of immunomodulation, including
production of anti-inflammatory cytokines (IL-10 or TGF-1), function as inhibitory antigen
presenting cells, and induction or recruitment of Tregs (181).
We have recently identified a novel putative Breg that may be involved in the regulation
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of airway inflammation (85). Acute aerosolized ovalbumin (OVA) exposure in sensitized mice
induces typical allergic airway disease (AAD), but chronic inhalational antigen exposure results
in resolution of the airway eosinophilia, Th2-cytokine secretion, and airway hyperreactivity
regardless of the persistence of OVA-specific IgE in serum and OVA-specific subcutaneous
allergic reactions (114, 119, 182-184). Reflecting the focal resolution of inflammation, we have
termed this process local inhalational tolerance (LIT). Adoptive transfer of regional hilar lymph
node (HLN) B cells from LIT mice to OVA-sensitized recipients increased the number of
CD4+CD25+Foxp3+ Tregs in BAL and attenuated AAD following subsequent OVA aerosol
exposure.21 In contrast to AAD HLN B cells or LIT splenic B cells, LIT HLN B cells produce
TGF- and are capable of converting naïve CD4+CD25– T cells into functionally suppressive
CD4+CD25+Foxp3+ regulatory T cells (Foxp3+ Treg) in vitro (85). These findings discovered a
regulatory role for regional B cells in the attenuation of inflammation and re-establishment of
homeostasis in the airway despite ongoing antigen challenge. The present study was undertaken
to further establish the phenotype of these Bregs and to investigate their relationship to Tregs in
respect to location in the HLN and in chemokine receptor expression.

RESULTS

CD5+ B cells were increased in the HLN at AAD and LIT
B cells isolated from inguinal lymph nodes and spleens were found to have an identical
phenotype in both AAD and LIT mice: CD21intermIgDhi IgMintermCD5lo, consistent with mature
follicular B cells. AAD HLN B cells had a similar phenotype to the cells in these systemic
tissues, whereas LIT HLN had increased percentage of IgDlo and CD5hi cells as compared to
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AAD (Figure 3). In the HLN, there was a significant increase (p < 0.005) in the total number of
CD5+ B cells in mice at AAD and LIT as compared to mice in the Naïve and Sensitized groups
and to any of the groups in inguinal lymph nodes (Figure 4A). In the inguinal nodes, there were
no significant differences in the total number of CD5+ B cells in mice at any of the stages
(Figure 4A). Also in the HLN, there was a significant increase (p < 0.005) in the percentage
CD5+ B cells in mice at LIT as compared to mice in the Naïve, Sensitized and AAD groups and
to any of the groups in the inguinal nodes (Figure 4B). In contrast, in the inguinal lymph nodes,
there were no significant differences in the percentage of CD5+ B cells in mice at any of the
stages (Figure 4B).

LIT HLN CD5+ B cells predominantly express TGF-
The selective expansion of CD5+ B cells in HLNs from LIT mice suggested that these
cells could constitute the suppressive Breg phenotype identified previously, where B
lymphocytes isolated from HLNs of LIT mice induced CD4+CD25+Foxp3+ T cells via
expression of TGF-. Thus, this study assessed whether the LIT HLN TGF -producing B
cells resided in the CD5+ or CD5– cell population. Minimal LAP expression was seen in CD5+ or
CD5– cells isolated from spleens of Naïve or LIT mice (0.08-0.2% of these B cells were LAP+;
(Figure 5A and 5C). LAP was found at low levels in both types of B cells from HLN of Naïve
mice. Its expression increased in both CD5+ and CD5– B cells in HLN from LIT mice, but the
enhanced expression was much more dramatic in the CD5+ LIT HLN B cell population. In LIT
HLNs, 37.9 ± 9% of CD5+ B cells were LAP+, as compared to 13.3 ± 4% of CD5– B cells (p =
0.042; Figure 5C). As anticipated, little IL-10 staining was seen in unstimulated B cells, but IL10 production could be induced by 5-hour stimulation with phorbol 12-myristate 13-acetate and
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ionomycin. As shown in Figures 5B and 5D, IL-10 was also primarily produced by CD5+ B cells
(8.2 ± 1.3% in LIT HLN and 5.2 ± 0.7% in LIT spleen) than by CD5- B cells (1.0 ± 0.3% in LIT
HLN and 0.6 ± 0.1% in LIT spleen; p < 0.0005 each). Unfortunately, the LAP staining was poor
in these studies, possibly because of interference from the IL-10 staining conditions (e.g.,
permeabilization, low temperature), and so co-expression of IL-10 and TGF- could not be
directly assessed. However, in contrast to TGF-, IL-10 production did not differ between LIT
HLN and LIT spleen CD5+ B cells (p = 0.074), and in the HLNs, CD5+ B cell expression of IL10 was significantly less than their expression of TGF- (p = 0.0015; Figure 5D).

LIT HLN CD5+ B cells induced formation of Foxp3+ T cells in vitro, and adoptive transfer of
LIT HLN CD5+ B cells increased airway Foxp3+ Tregs in sensitized recipient mice
We have previously demonstrated that LIT HLN B cells can induce Foxp3 expression in
naïve T cells in vitro through a mechanism dependent on TGF- and independent of IL-10 (21).
To determine if functional distinctions corresponded to the differential expression of LAP/TGF-
in CD5+ versus CD5– HLN B cells, CD19+ B cells that were isolated from HLNs of LIT mice
were divided into CD5+ and CD5– populations, irradiated, and then co-cultured with naïve
splenic CD4+CD25– T cells and anti-CD3/CD28. Foxp3+ expression by the T cells was increased
3-fold by LIT HLN CD5+ B cells relative to control stimulated conditions, but the LIT HLN
CD5– B cells were without effect (Figure 6A).B cells were also required for the in vivo
expansion of Foxp3+ Treg cells during LIT. In a first series of experiments, the progression of
AAD to LIT was compared in wildtype mice and in B-cell-deficient JhD–/– mice (Jackson
Laboratory, Bar Harbor, ME). Wildtype mice showed regional expansion of Foxp3+ T cells
during LIT, occurring in hilar but not inguinal lymph nodes (Figure 6B). This regional
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expansion also occurred in the JhD–/– mice (p < 0.005). Next, adoptive transfer studies were
performed with LIT HLN CD5+ B cells, LIT HLN CD5– B cells, and LIT Spleen CD5+ B cells.
The number of airway Foxp3+ Tregs present in bronchoalveolar lavage of AAD mice increased
by 43% in mice receiving LIT HLN CD5+ B cells (0.70 ± 0.1 x 105 cells) as compared to saline
control mice (0.5 ± 0.1 x 105 cells) but was not affected by the adoptive transfer of LIT HLN
CD5– B cells or LIT splenic CD5+ B cells (Figure 6C). Moreover, there was a direct correlation
between the number of airway Foxp3+ Tregs and airway CD5+ B cells (r = 0.56; p < 0.005;
Figure 6D). This correlation did not hold between airway Foxp3– Teff cells and CD5+ B cells in
(r = 0.27; p = 0.20) or between airway Foxp3+ Tregs and CD5– B cells (r = 0.31; p = 0.14; data
not shown).

Foxp3+ Tregs increased in the B cell zone and T cell - B cell border of the HLN via confocal
microscopy in mice at LIT
The expansion of airway and HLN Foxp3+ cells from AAD to LIT was associated with a
striking difference in the distribution of Foxp3+ Tregs in HLNs, with fewer Foxp3+ Tregs at AAD
as demonstrated in the confocal microscopy images (Figure 7 A-C). Qualitative observations of
confocal images showed apparent increases of Foxp3+ Tregs in HLN of mice at LIT (Figure 4A,
lower panel) as compared to sensitized and AAD stages (Figure 7A, upper and middle panels).
These observations were supported by quantification of Foxp3+ Tregs and B cells in different
compartments of the HLN which included T cell zone, T cell - B cell border (T-B border), and B
cell zone (follicle). Representative images for the quantification strategy of Foxp3+ Tregs in the
T-B border are shown in Figures 7B and 7C. In general, the B cell zones (follicular area) were
reduced in size and number of cells in the HLN at LIT as compared to AAD, corresponding with
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the resolution of lung inflammation (Table 1). There was a 78.3% increase (p < 0.05) in the
density of Tregs (follicular Tregs) in the follicular B cell zone of HLN from mice at LIT as
compared to AAD (Figure 7D), with no changes in Foxp3+ Treg densities in the T cell zone and
T-B border. Moreover, in the T-B border and B cell zone, the ratios of Foxp3+ Tregs to B cells
increased 184% and 146%, respectively, in HLN from mice at LIT as compared to AAD (Figure
7E; (p < 0.05 each). These data show that Foxp3+ Tregs preferentially localized in the follicular
area of the HLN at LIT. CD5 staining was not bright enough to permit specific identification of
CD5+ B cells by confocal microscopy.

The number of CD5+ B cells and Foxp3+ Tregs expressing CXCR4 and CXCR5 were
increased in the HLN at AAD and LIT
The co-localization of B cells and Foxp3+ T cells in HLNs suggested that the cells could
be expressing similar chemokine receptors. Thus, the expression of CXCR4 and CXCR5 on
CD5+ B cells and Tregs was compared between hilar and inguinal lymph nodes and at various
stages of the OVA model (Naïve, Sensitized, AAD and LIT). Significantly more CD5+ B cells
expressed CXCR4 in hilar nodes versus inguinal nodes at each stage of the model (p < 0.05;
Figure 8B), and this regional expression increased further at AAD and LIT as compared to
Naïve and Sensitized stages (p < 0.05). Moreover, within hilar lymph nodes, expression of
CXCR4+ was 2.3 to 3.5 fold higher on CD5+ B cells than on CD5– B cells at all stages of the
model (Figure 9). In contrast, there were no changes observed in the percentage of CXCR4+
CD5+ B cells in the inguinal lymph nodes except for a significant decrease at the Sensitized
stage. There was no difference in the percentage of CD5+ B cells expressing CXCR5 at any of
the stages in hilar or inguinal lymph nodes (Figure 8C). Like the percentages, the total number
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CD5+ B cells expressing CXCR4 was significantly increased in the HLN of mice at AAD and
LIT as compared to mice at Naïve and Sensitized stages (Figure 10A), and the total number of
CD5+ B cells expression CXCR5 was also increased at AAD and LIT (Figure 10B). The number
of CD5+ B cells expressing CXCR4 and CXCR5 was not altered in the inguinal lymph node at
any of the stages (Figure 10A and B).

The percentage (Figure 11B) and total number (Figure 10C) of Foxp3+ Tregs expressing
CXCR4 were increased in the hilar nodes in mice at AAD and LIT, as compared to Naïve and
Sensitized groups (p < 0.005), with no changes seen in inguinal nodes. In contrast to CD5+ B
cells in the HLN, the percentage of Foxp3+ Tregs expressing CXCR5 was significantly increased
in mice at AAD and LIT as compared to Naïve and Sensitized stages (p < 0.005; (Figure 11C).
In the ILN, the percentage of CXCR5+ Foxp3+ Tregs was not altered at any of the stages (Figure
11C). Similarly, the total number of Tregs expressing CXCR5 was significantly increased in
mice at AAD and LIT as compared to mice in Naïve and Sensitized stages (Figure 10D). These
data show that both CD5+ B cells and Tregs up-regulate the expression of CXCR4 and CXCR5
at AAD and LIT specifically in HLN and not in the ILN.

Adoptive transfer of LIT HLN CD5+ B cells attenuated airway eosinophilia in sensitized
recipient mice
The association between CD5+ B cells and Foxp3+ Tregs suggested that the regional HLN
B cells responsible for the previously reported attenuation of AAD21 resided in the CD5+
population. To test this, the degree of AAD was compared in animals receiving LIT HLN CD5+
B cells. The development of airway eosinophilia was significantly reduced in mice that received
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LIT HLN CD5+ B cells (60.6 ± 2.0% and 17.2 ± 2.6 x 105 eosinophils) as compared to mice that
received either vehicle alone, LIT HLN CD5– B cells or LIT spleen CD5+ B cells (Figure 12).
Mice receiving LIT spleen CD5– B cells, naïve spleen CD5– B cells, or naïve spleen CD5+ B
cells also developed similar airway eosinophilia as the control recipient animals (data not
shown).

DISCUSSION
Previously we have shown that regional B cells isolated from hilar lymph nodes of LIT
mice are capable of suppressing AAD in recipient animals. B cells from LIT HLNs are unique in
this function, as AAD suppression is not exerted by B cells isolated from AAD HLN or by
splenic B cells of either AAD or LIT mice. These LIT HLN Bregs induce Foxp3+ T cell
generation through expression of TGF- (85). The present study further characterized these
Bregs as a unique local CD19+B220+CD1dloCD5+ B cell population expressing TGF- and upregulated expression of the chemokine receptor CXCR4.
The finding of CD5+ cells in LIT HLNs was distinctive, as there are very few reports of
CD5+ cells in draining lymph nodes (185). Their presence, in part, could be attributed to their
expression of the chemokine receptors CXCR4 and CXCR5. The high level of CXCR5
expression by all the HLN and ILN B cells was consistent with its constitutive expression on
circulating B cells, which directs their homing to B-cell follicles (186, 187). The upregulation of
CXCR4 on HLN CD5+ B cells at AAD and LIT would direct their localization to germinal center
dark zones, which are located adjacent to T-cell areas (188). Further, the observation of
increased expression of CXCR4 and CXCR5 on HLN Foxp3+ Tregs during AAD and LIT would
facilitate their interaction with follicular B cells by placing Bregs and Foxp3+ Tregs in close
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proximity in the HLN. Foxp3+ Treg cells are known to express CXCR4 (189), and so the
increased numbers of CXCR4+Foxp3+ Treg cells in HLNs of AAD and LIT mice may have been
due to enhanced migration of existing Foxp3+ Treg cells to the HLN. Alternately, the ability of
LIT HLN CD5+ B cells to convert naïve CD4+ T cells to suppressive Foxp3+ Treg cells raises the
intriguing possibility that this conversion is occurring in the HLN follicles, initially during AAD
to help limit the inflammatory response and continued at LIT to sustain the reestablished airway
homeostasis. The confocal images support the close localization of these regulatory cells in the
HLN especially in the T-B border, both qualitatively and quantitatively.
Other investigators have implicated a regulatory role for B-1a CD19+CD5+ cells in
moderating allergic airway disease. In a cockroach allergen-induced asthma model, mice that are
deficient in B-1a cells (CBA/CaHN-Btkxid/J mice) develop higher serum IgE levels and more
airway inflammation than wild type mice (190). It should be noted, however, that Xid mice have
several B-cell abnormalities, including impaired survival of follicular IgDhiIgMlo B cells and
reduced numbers of marginal zone B cells (191). Thus, potential abnormalities in other
regulatory B cell populations in Xid mice could have accounted for their increased allergic
airway disease. The IgDloCD5hi phenotype also suggested a B-1 rather than B-2 cell morphology
in our subpopulation of LIT HLN B cells; however, all the cells were also B220+ (e.g.,
CD45Rhi), which is associated with B-2 cells. Thus, the expanded population of CD19+CD5+
cells in LIT HLNs had characteristics of both B-1 (IgDlo) and B-2 (B220+) subsets, and therefore
may reflect a previously undefined Breg cell population that arose with chronic antigen
exposure. Indeed, while CD5 expression is characteristic of B-1 cells, this surface marker can
also be induced in B-2 cells by a variety of stimuli (192). CD5 expression can be induced in
human peripheral blood B cells by co-cultivation with T cells via CD40-CD40L interaction, and
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these CD5+ B cells have T-cell suppressive activity (193). Since our LIT mice are chronically
exposed to OVA for 6 weeks, the CD5+ cells seen in their HLN may represent induced
expression of the marker by non-B-1 cells.
In our LIT model, the suppressive Bregs arose only in regional HLNs, and no suppressive
B cells were found in spleen or inguinal lymph node tissues. Moreover, the LIT hilar nodes
contained 5-fold more TGF-+ cells than IL-10+ cells. Of interest, CD19+ B cells from regional,
mesenteric lymph nodes of mice with chronic enteric helminth infections are also capable of
suppressing AAD through an IL-10–independent mechanism (194). In addition, both IL-10
producing CD19+CD5+ B cells (B-10 cells) and TGF -producing CD19+CD5+ B cells have been
shown to regulate cow’s milk allergic responses in human subjects (168, 195). TGF -expressing
B cells have been shown to down-regulate pathogenic Th1 immunity in nonobese diabetic mice
(148), but an analogous pathway has not been observed previously in a Th2 inflammatory model
such as AAD. As with T cells, it is likely that several populations of regulatory B cells exist, and
that different subsets may be preferentially generated based on the types of stimuli and
anatomical sites of antigen presentation.
Our studies have shown that LIT does not depend on the presence of either Bregs or
Foxp3+ Tregs in knockout or antibody-depleted animals (85, 195). Although B-cell knockout
animals develop LIT, they do so despite diminished levels of regional Foxp3+ Tregs. This
finding supports the complex and interactive contributions of Bregs and Tregs in the
development of tolerance in wild type animals. Indeed, the contrasting pro- and antiinflammatory roles of B and T cells are likely to overlap in asthma, with the balance of these
opposing actions determining the natural course of the disease.
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Figure 3. Unique B cell population in LIT hilar lymph nodes. Figure illustrates representative
histograms of isotype control (green), B cells from AAD mice (red), and B cells from LIT mice
(blue) isolated from inguinal lymph nodes (ILN; top row) and hilar lymph nodes (HLN; bottom
row). First Column: CD21 expression was consistent between all groups and compartments.
Second Panel: IgM expression was consistent between all groups and compartments. Third
Column: IgD expression was decreased on LIT HLN B cells, as compared to AAD HLN B cells
and AAD or LIT ILN B cells. Fourth Panel: CD5 expression was increased on LIT HLN B
cells, as compared to AAD HLN B cells and AAD or LIT systemic B cells.
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Figure 4. CD5+ B cells were increased in the HLN at AAD and LIT. Cells were isolated
from hilar (black bars) and inguinal lymph nodes (grey bars) at different stages of the OVA
model (Naïve, Sensitized, AAD and LIT). Panel A depicts flow cytometry dot plots from
representative tissues, and panels B and C show mean ± s.e.m values for total number (B) and
percentage of CD5+ B cells (C). Numbers of CD5+ B cells were significantly expanded in hilar
nodes at AAD and LIT, and they remained elevated as a percentage of total B cells during LIT.
In contrast, no changes were seen in the inguinal nodes. n = 8-12 in each group. ** indicates p <
0.005 as compared to naïve and sensitized groups in hilar nodes and to all groups in inguinal
nodes (Panel B), or p < 0.005 as compared to all other groups (Panel C).
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Figure 5. Anti-latency-associated protein (LAP) and interleukin (IL)-10 expression in CD5+
and CD5– B cells. Lymphocytes isolated from Spleens and hilar lymph node (HLN) of Naive
and local inhalational tolerance (LIT) mice were stained for B220, CD5, anti-latency-associated
protein (LAP), and IL-10, as described in the text. Panels a and b depict flow cytometry dot blots
from representative tissues, and panels c and d show mean ± s.e.m.values for LAP expression (c)
and IL-10 expression (d) in CD5 + (black bars) and CD5 – B cells (gray bars). (c) Relative to
Naive animals, LAP expression was unchanged in spleen CD5+ and CD5– B cells of LIT mice,
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but LAP expression increased in HLN CD5 + and CD5 – B cells at LIT. (d) IL-10 levels were
increased in CD5+ B cells from both spleen and HLN compared with CD5– B cells, but there was
no difference in expression between LIT spleen and LIT HLN. n = 4 – 5 mice per group for LAP
and 6 mice per group for IL-10 staining. * * P < 0.001 from other groups by ANOVA;
† P < 0.05 for CD5+ cells vs. CD5– cells.

55

Figure 6. In vitro and in vivo dependence of Foxp3+ Treg (regulatory T lymphocytes) cells
on CD5+ B cells. (a) CD4 + CD25 – T cells from spleens of naive mice were co-cultured for 5
days without or with stimulation by soluble anti-CD3 and anti-CD28. Stimulated (Stim) cells
were also co-cultured with either irradiated CD19 + CD5 + B cells or CD19 + CD5 – B cells from
local inhalational tolerance (LIT) hilar lymph nodes (HLNs). T-cell Foxp3 expression was
increased when cultured with LIT HLN CD5 + B cells vs. with LIT CD5 – B cells or anti-CD3 /
CD28 alone. Data represent mean ± s.e.m. values of 3 – 4 animals per group; * * P < 0.01 vs.
other groups by analysis of variance (ANOVA). ( b ) Foxp3 + Treg expression was compared in
LIT control and JhD – / – mice. Control (CRL) mice showed expansion of Foxp3 + Treg cells in
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hilar nodes (black bars) but not inguinal nodes (striped bars), but this local expansion did not
occur in the JhD – / – mice. n = 5 mice per group; * P < 0.005 between CRL and JhD – / – mice. (c)
Two days before a week of daily ovalbumin (OVA) aerosol exposures, OVA-sensitized mice
received tail vein injections of saline or specific B-cell populations. Mice receiving LIT HLN
CD5 + B cells demonstrated increased numbers of Foxp3 + T cells in their bronchoalveolar
lavage (BAL), as compared with control (saline) mice or mice receiving LIT HLN CD5 – B cells
or LIT spleen (SPL) CD5 + B cells. n = 5 – 11 mice per group; * P < 0.05 vs. other groups by
ANOVA. (d ) For all groups of mice in panel c , there was a direct correlation between the
number of CD4 + Foxp3 + Treg cells and the number of CD19 + CD5 + B cells in BAL
(dashed line; r = 0.56; P < 0.005). This relationship also held for the LIT HLN CD5 + recipient
animals alone (solid line; r = 0.73; P < 0.05). By contrast, there was no association between
CD4+ CD25 + Foxp3 – Teff (Th2 effector lymphocytes) cells and CD19 + CD5 + B cells in BAL
(r = 0.28; P > 0.10; data not shown).
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Figure 7. Increased Foxp3+ Tregs in the follicular area of the HLN in mice at LIT via
confocal microscopy. Confocal microscopy was performed on HLNs from mice after
sensitization (white bars), at AAD (grey bars), and at LIT (black bars) to determine the locations
of B cells and CD4+Foxp3+Treg cells. Panels A-C: Representative confocal images of HLNs
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from sensitized (upper panels), AAD (middle panels), and LIT mice (lower panels), with
quantification assessed using Imaris software as described in methods. Regions of appropriate
dimensions were selected along the T-B border for quantification of Foxp3+ Tregs in that area
(B). Foxp3+ Tregs were enhanced using the spots tool in Imaris Suite (C) and counted.
Representative colors for confocal microscopy: green B220+ cells, blue CD4+ cells, and red
Foxp3+ cells. Images of magnification 20x. Panels D-E: Mean ± SEM values for Foxp3+ Treg
cell density (D) and the ratio of the number of Tregs to B cells (E) in the different HLN zones.
compartments. n = 6-8 specimens per group; * indicates p < 0.05 as compared to sensitized and
AAD in T-B border and B cell zone.
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Figure 8. Hilar lymph node CD5+ B cell expression of CXCR4 and CXCR5. CD5+ B cells
were isolated from hilar nodes (black bars) and inguinal nodes (gray bars) at different stages
(Naïve, Sensitized, AAD and LIT) of the OVA model. Panel A depicts representative flow
cytometry dot plots of CXCR4 expression on CD19+CD5+ B cells. Panel B demonstrates
increased CXCR4+CD5+ B cells in hilar compared to inguinal lymph nodes at all stages of the
model, and expansion of hilar node CXCR4+CD5+ B cells during AAD and LIT. Panel C
demonstrates similar CXCR5 expression by CD5+ B cells in both tissues and at all stages of the
model. Data represent the mean ± S.E.M; n = 8-12 in each group (A, B); * indicates p < 0.05 as
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compared to Naïve and Sensitized groups in the HLN and to all groups in the ILN; ! indicates p
< 0.05 as compared to all groups in the ILN; † indicates p < 0.05 between HLN and ILN in
Naïve and Sensitized groups; †† indicates p < 0.005 between HLN and ILN in AAD and LIT
groups.
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Figure 9. Increased expression of the chemokine receptors CXCR4 and CXCR5 by CD5– B
cells and Foxp3– T cells in the HLN at AAD and LIT. Cells were isolated from hilar (black
bars) and inguinal nodes (grey bars) at different stages (Naïve, Sensitized, AAD and LIT) of the
OVA model and flow cytometric analysis was performed. Data represent the mean ± S.E.M; n =
8-12 in each group (A, B), n = 4-8 in each group (C, D). * indicates p < 0.05 as compared to
Naive and LIT groups in ILN and to all groups in HLN (panel A) and as compared to Naïve and
Sensitized groups in HLN and to all groups in the ILN (panel C); † indicates p < 0.05 between
HLN and ILN in Sensitized, AAD and LIT groups. ! indicates p < 0.05 as compared to all groups
in HLN; as compared to all groups in ILN.
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Figure 10. The number of CD5+ B cells and Foxp3+ Tregs expressing CXCR4 and CXCR5
were increased in the HLN at AAD and LIT. Cells were isolated from hilar (black bars) and
inguinal nodes (gray bars) at different stages (Naïve, Sensitized, AAD and LIT) of the OVA
model and flow cytometric analysis was performed. CXCR4 and CXCR5 expression was
increased on CD5+ B cells (A, B) and on Foxp3+ Tregs (C, D) in hilar lymph nodes but not in
inguinal lymph nodes. Data represent the mean ± S.E.M of 8-12 in each group (A, B) and 4-8 in
each group (C, D). ** indicates p < 0.005 as compared to Naïve and Sensitized groups in HLN
and to all groups in ILN.
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Figure 11. Hilar lymph node Foxp3+ T cell expression of CXCR4 and CXCR5. Foxp3+ T
cells were isolated from hilar nodes (black bars) and inguinal nodes (gray bars) at different
stages (Naïve, Sensitized, AAD and LIT) of the OVA model. Panel A depicts representative
flow cytometry dot plots of CXCR4 and CXCR5 expression on CD4+Foxp3+ T cells. Panel B
demonstrates increased CXCR4+Foxp3+ T cells in hilar compared to inguinal lymph nodes at
AAD and LIT, and expansion of hilar node CXCR4+Foxp3+ T cells during AAD and LIT. Panel
C demonstrates expansion of hilar node CXCR4+Foxp3+ B cells during AAD and LIT. Data
represent the mean ± S.E.M; n = 4-8 in each group (A, B); ** indicates p < 0.005 as compared to
Naïve and Sensitized groups in the HLN; †† indicates p < 0.005 between HLN and ILN in AAD
and LIT groups.
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Figure 12. Attenuation of AAD by adoptive transfer of LIT HLN CD5+ B cells into
sensitized recipient mice. OVA-sensitized mice received tail vein injections of saline or specific
B cell populations (0.2 x 106 CD19+CD5+ or 1.0 x 106 CD19+CD5– cells) 2 days before a week
of daily exposure to 1% OVA aerosols. Mice receiving the LIT HLN CD5+ B cells (solid bars)
developed attenuated AAD, with less relative (Panel A) and absolute (Panel B) airway
eosinophilia relative to control (saline) mice or mice receiving LIT HLN CD5– B cells or LIT
spleen CD5+ B cells. Data represent mean ± S.E.M values of 5-11 mice per group; * indicates p
< 0.05 vs. other groups by ANOVA.
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Increased Foxp3+ Tregs in the follicular area of the HLN in mice at LIT via confocal
microscopy.

AAD
B cell zone

T-B cell
border

T cell zone

LIT

B220

928 ± 105 509 ± 85 *

Foxp3

108 ± 14

191 ± 31 *

B220

312 ± 58

242 ± 27

Foxp3

87±12

205±36 *

B220

284±59

174±85 *

Foxp3

387±63

536±138

Table 1.
Data represent mean ± S.E.M values; * indicates p ≤ 0.05 as compared to AAD; n = 6-8.
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CHAPTER 4

ALLERGIC AIRWAY DISEASE AND INHALATIONAL TOLERANCE
DEVELOP LOCALLY IN THE LUNG COMPARTMENTS AND
ARE NOT DISTRIBUTED TO OTHER MUCOSAL SITES

INTRODUCTION
In the OVA model of AAD, we have well established that continued antigen exposure
(beyond peak inflammation) results in the spontaneous resolution of airway disease and the
development of LIT. Footpad injection of OVA into LIT mice results in a DTH (delayed type
hypersensitivity) reaction (118), which demonstrates that the tolerance established to OVA is not
systemic and may be local to the lung compartments (BAL, lung tissue and the HLN) or
distributed within the mucosal system. The cellular environment shifts from a pro-inflammatory
state towards a regulatory state during the development of LIT in the HLN, which is evidenced
by increased numbers and frequency of Foxp3+ Tregs. Unique to our model, we also observe an
increase in the frequency of CD5+ Breg cells in HLN at LIT with suppressive functions and not
in systemic lymphoid tissues like the spleen and inguinal lymph node (151).
A unique feature of the mucosal immune system is to protect mucosal surfaces from
pathogen attack independent of the systemic immune system, and extensive studies showed the
trafficking of activated antigen-specific T cells and B cells from the mucosal site of antigen
challenge to other distant mucosal sites (196, 197). The respiratory tract is one of the three
constituents of the mucosal system; which also includes the gastro-intestinal (GI) and urogenital
tracts. The central dogma of cellular distribution that links remote mucosal sites was proposed in
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the late 1980s, and led to the concept of the common mucosal immune system (198). Although it
was originally proposed that activated IgA- committed B cells and T helper cells distribute
equally to all compartments of the mucosal system, it later became evident that there existed a
compartmentalization within these sites; and studies showed that the distribution of immune cells
from the respiratory tract was more limited than from the GI tract (199, 200).
A plethora of recent investigations have established the trafficking of immune cells
between the GI tract and lung compartments and also to systemic circulation (198-201). These
concepts raised the question of whether the tolerance developed in our model of AAD is purely
local to the lung compartments or if the regulatory cells traffic to or from the GI mucosal
immune system. In our method of antigen delivery via the aerosol route, it is likely that some
OVA is swallowed and enters the GI tract. This intrigued us to study the mesenteric lymph nodes
(MLN) which are the draining lymph nodes of the intestines and a central site for development of
oral tolerance (202, 203). Since the lung and GI tract comprise major components of the mucosal
immune system and cellular trafficking occurs between both systems, we hypothesized that an
increase in Foxp3+ Tregs would also be observed in the MLN at LIT as seen in the HLN. To this
end, we isolated lymphocytes from the MLNs and analyzed the frequency of regulatory T cells
and B cells at naïve, sensitized, AAD and LIT stages, and compared the frequencies to those in
the HLN and ILN at the corresponding stages. Confocal microscopy was also employed to
characterize the trafficking of Tregs within the MLNs at the various stages in our model.

68

RESULTS

Note: There was a considerable variability in the number of MLNs that were isolated from each
mouse, which led to high variability in the total number of MLN cells between mice from the
same group. Hence, in the following figures we represent the data only as frequencies which is
more representative of the actual outcome than total numbers.

Increase in the frequency of regulatory T cells and B cells in the MLN was not observed in
any stage of the OVA-induced model of AAD
To examine whether there is trafficking of Tregs between the HLN and MLN during the
induction of tolerance in our model, we isolated lymphocytes from the HLN, MLN and ILN and
analyzed the T cells for the expression of Foxp3+ via flow cytometry. The frequency of Foxp3+
Tregs remained unchanged in the MLNs of mice at naïve, sensitized, AAD and LIT stages of the
model. This trend was similar to what was observed in the ILNs, which serve as systemic control
in our model (Figure 13). Contrary to the MLNs, in the HLNs there was an increase (p < 0.05)
in the frequency of Tregs at LIT as compared to any other stage which correlates with our
previous publications.

Another important class of regulatory cells in our model are the CD5+ B cells (Bregs)
which express TGF-β on their surface (151)(151). At steady-state CD5+ B cells are present
predominantly in the peritoneal and pleural cavity (35 to 70% of B cells) and at a very low
frequency in the spleen, ~2% (204-206). In our model at LIT, we observed that about 5% of the
total B cells are CD5+ in the HLN only at LIT (151). Hence, we investigated whether there is
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trafficking of CD5+ B cells between the MLN and HLN during the induction of tolerance. To
this end, we isolated lymphocytes from the several lymph nodes as mentioned above and
analyzed the expression of CD5 on the surface of B cells. In naïve mice and at all stages of the
OVA-induced AAD model, the frequency of CD5+ B cells was greater in the MLN as compared
to the HLN or ILN. However, there was no significant increase in the frequency of CD5+ B cells
in the MLN of mice at LIT as compared to other stages (Figure 14). Again, this pattern was
similar to what was observed in the ILN at all stages of the model. In parallel to our previous
publication (151), the frequency of CD5+ B cells in the HLN of mice at LIT was increased as
compared to any other stages. Thus, the MLNs do not show obvious changes in the frequencies
of Tregs and CD5+ B cells at any of the stages throughout the model, in contrast to the HLN.

OVA tetramer+ CD8 T cells do not accumulate in the MLN during peak disease or tolerance
We have previously shown that the levels OVA-specific CD8 T cells peak during acute
disease and their frequencies still remain elevated at LIT in the HLN. We also showed that these
OVA-specific CD8+ T cells exhibit plasticity from a pro-inflammatory phenotype at AAD
(increased granzyme B and IFN γ) to a suppressive phenotype (NKG2A+, decreased granzyme B
and IFN γ) at LIT (207). As CD8+ T cells seem to play an active role during establishment and
resolution of disease in our model, we examined whether administration of OVA via the aerosol
route in a Th2 setting would lead to the trafficking of OVA-specific CD8+ T cells between the
lung compartments and the MLN. To address this, we analyzed CD8 T cell subsets from the
MLN of mice at naïve, sensitized, AAD and LIT stages.
As we expected, the frequency of CD8+ CD11ahi OVA-tetramer (Otet)+ T cells in the
MLNs of naïve and sensitized mice was very low (~0.1%), similar to what was observed in the
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HLN and ILN. Interestingly, the frequency of OVA-specific CD8 T cells did not increase in the
MLN even during peak inflammation – AAD, unlike in the HLNs where we observed increased
frequency of Otet+ CD8+ T cells at AAD and LIT as compared to other stages (p < 0.005). In the
MLNs, the frequency of this cell type also remained unchanged at LIT (Figure 15). This
observation suggests that in our model, the MLNs remain quiescent during AAD and LIT similar
to systemic lymphoid tissues such as the ILN and spleen.

Foxp3+ Tregs do not cluster in the B cell follicles of the MLNs from mice at LIT
Finally, to confirm that there was no trafficking of regulatory lymphocytes between the
pulmonary and intestinal immune system, we assessed the localization of Tregs in the different
compartments – T cell zones and B cell follicles of the MLN at naïve, sensitized, AAD and LIT
stages of the model. Our earlier finding demonstrated that Foxp3+ Tregs preferentially localize in
the B cells follicles of the HLN at LIT, via confocal microscopy (151). In the MLNs, supporting
our other results, we did not observe clustering of Tregs either in the B cell follicle or in the T
cell zone at LIT or any other stage (Figure 16). In general, Tregs were more abundant in the T
cell zones as compared to the B cell follicles at all stages of the model. Also, unlike the HLN, we
did not observe expansion of B cell follicles in size or number in the MLNs at AAD as compared
to other stages.

DISCUSSION
From our studies using footpad injections of OVA in mice at LIT, we have
established that the immunological tolerance to the OVA antigen developed in our chronic model
of AAD is not systemic (118). For several decades, multiple investigations have supported the
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phenomenon of a common mucosal immune system, where immunization in one of the mucosal
organs (e.g., pulmonary mucosa) generates protective immunity in the other distant mucosal
tissues (GI and urogenital tract) and vice versa (199, 201). An interesting study showed that
pulmonary delivery of plasmid DNA formulation (PEI DNA) induced robust Ag-specific CD8+
T cell responses in the pulmonary, gut and vaginal mucosa of mice (200). On the other hand, the
gut-associated lymphoid tissue which is considered the largest immune organ of the body is the
primary route of antigen exposure; where induction of tolerance is the default pathway
employing several mechanisms such as induction of regulatory T cells, anergy and deletion of
effector T cells (208). Feeding mice with low doses of Ag has been proven in different studies to
increase Tregs in the MLNs (209, 210) and the MLNs being one of the central players for the
induction of oral tolerance (203).
These facts combined with the possibility of oral exposure of OVA in our method
of Ag delivery, primed us into thinking whether the tolerance developed in the lung
compartments is linked to the gut immune system. Hence, we investigated the occurrence of
Foxp3+ Tregs in the MLN at LIT which is the time point when these cells accumulate in the
HLN. On comparing the frequency of Tregs at naïve, sensitized, AAD and LIT stages of the
model in the MLN, we did not observe an increase in frequency at LIT unlike the HLN (Figure
11). We also studied the localization of Tregs in the different compartments within the MLNs at
the various stages of the model. On the contrary to what we expected, there was no preferential
localization of Tregs in the B cell follicles of the MLN at LIT (Figure 16). Similar to the Tregs,
we did not observe an increase in the levels of CD5+ B cells or OVA-specific CD8+ T cells in the
MLNs of mice at AAD or LIT (Figure 14 and 15). These data suggest that the MLNs do not play
a role with respect to regulatory T cell and B cell induction during the development of LIT.
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The main reasons which may explain why we do not see a response in the MLN at
AAD or LIT are as follows. Firstly: the dose of Ag delivered via the oral route. During aerosol
delivery of OVA, the mice are restrained in a nose only exposure chamber to enhance airway
delivery of the OVA, which inhibits swallowing of OVA by the mice. It is possible that the dose
of OVA Ag required to prime tolerance in the MLN is not swallowed by the mice, as we do not
monitor the amount of Ag that reaches the gut. This could be one of the reasons why we do not
find the involvement of the GI tract during peak inflammation and during the induction of
tolerance.
Secondly, the timing of Ag delivery could be responsible for the above mentioned
outcomes in the MLN. Antigen-speciﬁc immunotherapy for the treatment of allergies has been
studied in food allergies (210) and several models of AAD using OVA and house dust mite as
the antigen (209, 211). One such study demonstrated the development of tolerance to OVA,
when the Ag was delivered by oral gavage in mice that were already sensitized and challenged
with OVA. The oral gavage was followed by subsequent OVA aerosol challenges (210). In this
study, tolerance to OVA-induced airway inflammation was established by oral feeding of antigen
alone (no aerosol exposure) which is different from our method, where it is likely that the Ag is
swallowed during OVA aerosols. The method of Ag delivery could be another drawback in our
system which might prohibit the trafficking of regulatory cells between the HLN and MLN.
Nonetheless, it is also possible that the MLNs are involved through the course of
disease development and resolution in our system but may follow a different kinetics as
compared to the HLN and other lung compartments. Performing such studies at intermediate
time point before peak AAD (Day 3 or 5) and before LIT (Day 14, 21, 28) will provide
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conclusive evidence for role of the MLN and GI system in the induction of immunological
tolerance in our murine model of asthma.
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Figure 13. Changes in the frequency of Foxp3+ Tregs in the HLN, ILN and MLN at the
various stages of the OVA-induced AAD model. Black bars represent HLN, grey bars
represent ILN and white bars represent MLN at naïve, sensitized, AAD and LIT stages of the
model. Figure 13 depicts no changes in the frequency of Tregs at any of the stages in the MLNs
similar to the ILNs, unlike in the HLNs of mice at LIT which have increased frequency of Tregs
as compared to other stages. The data represent the mean ± s.e.m values. * p ≤ 0.05 as compared
to any other stage in HLN. n = 5-10 mice per group
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Figure 14. Frequency of CD5+ B cells remains unchanged throughout the OVA-induced
AAD model. Black bars represent HLN, grey bars represent ILN and white bars represent MLN
at naïve, sensitized, AAD and LIT stages of the model. Figure 14 demonstrates that the
frequency of CD5+ B cells does not increase in the MLNs of mice at LIT as compared to naïve,
sensitized and AAD stages similar to the ILNs. The data represent the mean ± s.e.m values. * p ≤
0.05 as compared to any other stage in HLN. n = 5-10 mice per group
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Figure 15. Changes in the frequency of CD8+ CD11ahi OVA- specific T cells in the HLN,
ILN and MLN at the various stages of the model. Black bars represent HLN, grey bars
represent ILN and white bars represent MLN at naïve, sensitized, AAD and LIT stages of the
model. Figure 15 depicts no changes in the frequency of CD8+ CD11ahi OVA tetramer+ T cells at
any of the stages in the MLNs similar to the ILNs, unlike in the HLNs of mice which have
increased frequency of CD8+ CD11ahi T cells at AAD and LIT as compared to naïve and
sensitized stages. The data represent the mean ± s.e.m values. ** p ≤ 0.005 as compared to naïve
and sensitized stages in HLN. n = 5-10 mice per group
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Figure 16. Localization of Foxp3+ Tregs in the different compartments of the MLN at the
various stages of OVA-induced AAD via confocal microscopy. Confocal microscopy was
performed on MLNs from mice at naïve, sensitized, AAD, and LIT stages of the model to
determine the locations of B cells and CD4+ Foxp3+ Treg cells. Representative confocal images
of MLNs from naïve, sensitized (upper panels), AAD and LIT mice (lower panels), with image
processed using the Imaris software. Foxp3+ Tregs were enhanced (red dots) using the spots tool
in Imaris Suite. Representation of cells: Green B220+ cells, blue CD4+ cells, and red Foxp3+
cells. Images of magnification ×20. Representative samples taken from an n of 4-5 mice per
group.
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CHAPTER 5

LOCAL INHALATIONAL TOLERANCE AND TISSUE SPECIFIC
REGULATORY B CELLS ARE INDUCED IN MICE LACKING
OVALBUMIN (OVA) SPECIFIC B CELLS

INTRODUCTION
Acute daily exposure of ovalbumin (OVA)-sensitized mice to aerosolized OVA for 7
days results in the development of allergic airway disease (AAD), a Th2-mediated inflammatory
process that demonstrates most of the characteristics of human asthma (212). However, the
continued daily exposure of mice to OVA aerosols beyond 3 weeks results in resolution of the
pulmonary AAD responses (114, 119, 124, 183, 184), and appears to be dependent on the
development of local inhalational tolerance (LIT). In this model, LIT is associated with an
accumulation of CD4+CD25+Foxp3+ regulatory T (Treg) cells in the hilar lymph nodes (HLN),
suggesting an important role for these cells in the resolution of AAD (195). In turn, these CD4+
CD25+Foxp3+ Treg cells appear to be generated by regional regulatory B (Breg) cells that
express CD5 and TGF-β (85, 151).
Another salient feature of the LIT response is bystander protection. Generation of LIT in
mice sensitized and chronically exposed to OVA protects the animals against AAD following
acute inhaled exposure to other allergens such as cockroach antigen (119) or to hen egg
lysozyme (HEL, (124)). These independent observations suggest that the process of LIT is not
antigen-specific. However, we have shown LIT to be Ag dependent since when OVA exposure
is discontinued, LIT is lost. Regional CD5+ TGF+ Breg cells generated in our LIT model appear
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to be antigen specific, as the adoptive transfer of OVA-derived Breg cells inhibits development
of AAD in OVA sensitized and acutely challenged recipient mice but not in bovine serum
albumin (BSA) sensitized and acutely challenged animals (85). Thus it remains uncertain
whether antigen specific B cells are required for the generation of LIT in this OVA-induced
model of AAD.
The present study aims at addressing this question of antigen specificity of the regional
Breg cells from the HLN of LIT mice, by studying the development of LIT and characteristic
functions of LIT HLN Breg cells in transgenic mice carrying rearranged immunoglobulin heavy
and light chain genes encoding a high-affinity anti-HEL antibody (C57BL/6Tg(IghelMD4)4Ccg/J mice). In these B cell receptor (BCR) transgenic mice, referred to as HEL
mice, almost 98% of the peripheral B cells express anti-HEL BCR and 94% of the B cells retain
their ability to bind HEL protein ex-vivo (213). Previous publications from our laboratory and
others (85, 86) using µMT and JhD-/- mice showed that AAD and LIT developed in mice that are
devoid of B cells. However, these B cell deficient mice have other immune related abnormalities
such as altered splenic architecture (214, 215), presence of immature DCs etc., which would
affect the outcomes of these studies. Thus, the HEL mice that have an otherwise normal immune
system and serve as a better tool to study the requirement of antigen-specific B cells for the
induction of LIT using our OVA-induced model of asthma.

RESULTS

HEL mice develop AAD and LIT in a similar manner as WT mice
To examine the development of AAD and LIT in HEL mice (lacking OVA-specific B
cells), sensitized WT and HEL mice were aerosol challenged with OVA as described in the
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methods. There was no difference in the total number of WBCs in the BAL of naïve HEL mice
as compared to naïve WT mice (Figure 17). At AAD, both WT and HEL mice had
approximately a 15 fold increase in the total number of WBCs as compared to the respective
naïve controls (Figure 17). At LIT, the number of WBCs in BAL of HEL mice was significantly
reduced (p < 0.02) as compared to HEL mice at AAD but remained elevated as compared to
naïve HEL mice. This observation was similar to what occurs in WT mice (Figure 17).
Analysis of WBC differential counts demonstrated that BAL of naïve HEL mice had a
similar cellular composition as compared to naïve WT mice with greater than 95% macrophages
and almost no eosinophils (Table 2). The BAL fluid of HEL mice at AAD demonstrated
increased numbers and frequency of eosinophils similar to WT AAD mice, a classic hallmark of
allergic asthma. Interestingly, the frequency of macrophages and polymorphonuclear cells
(PMNs) in HEL mice were significantly increased (p < 0.05) as compared to WT mice at AAD.
Further analysis of the BAL differential counts at LIT showed that the HEL mice resolved
eosinophilia in both numbers and frequency (Table 2). This data shows that tolerance is induced
in HEL mice following chronic antigen exposure as previously observed in WT mice.

Similar increases in T cell and B cell subsets in HEL mice as compared to WT mice at AAD
and LIT
AAD: To further demonstrate the development of AAD and LIT in HEL mice,
lymphocytes from HLN and lung (Figure 18) were isolated and the number of different T cell
subsets and B cells were analyzed using flow cytometry. At naïve stage, the total number of
lymphocytes and different subsets of T cells and B cells were similar between WT and HEL
mice. At AAD (Figure 18 a & b), HEL mice demonstrated a significant (p < 0.005) ~10 fold
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increase in the total number of lymphocytes in the HLN as compared to naïve HEL mice. This
increase was similar to that in WT mice. There was an ~8 fold increase (p < 0.005) in the total
number of CD4+ and CD8+ HLN T cell populations; and ~40 fold increase (p < 0.005) in HLN B
cell numbers in HEL mice at AAD as compared to the naïve HEL mice (Figure 18 a). In the
lung tissue, there was approximately ~2 to 3 fold increase (p < 0.005) in the total lymphocyte
number, CD4+ and CD8+ T cells and B cells at in HEL mice at AAD as compared to naïve HEL
mice similar to WT mice (Figure 18 b). These data collectively demonstrate the development of
full blown disease in HEL mice. Interestingly, the number of Tregs in the lung of HEL mice at
AAD was decreased (p < 0.05) as compared WT mice.

LIT: In HEL mice, there was ~5 fold and ~2 fold reduction in the total number of
lymphocytes in the HLN (Figure 18 a & c) and lung (Figure 18 b & d) respectively, at LIT as
compared to AAD, in a similar manner observed in WT mice. We also observed an ~8 fold
decrease in the B cell numbers and ~2 fold decrease in CD4 and CD8 T cell number in HLN of
HEL mice at LIT as compared to HEL mice at AAD; but remained elevated (p ≤ 0.05) as
compared to naïve HEL mice. These data, thus confirm the induction of tolerance in HEL mice
following chronic antigen exposure. Interestingly, the number of Tregs and activated CD8+
CD11ahi T cells in the HLN but not the lung of HEL mice were decreased (p < 0.05) as
compared to WT mice at LIT (Figure 18 c).
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LIT HLN B cells from WT and HEL mice induced the formation of CD4+ Foxp3+ Treg cells
in-vitro
We next investigated whether B cells isolated from the HLN of LIT HEL mice could
induce Foxp3+ expression in splenic CD4+ CD25− Foxp3− T effector (Teff) cells, as observed
previously in WT mice (85). Prior to co-culture with B cells, ~0.8% of the Teff cells expressed
Foxp3 (Figure 19 a). LIT HLN B cells from HEL mice significantly induced the expression of
Foxp3 in the Teff cells comparable to WT LIT HLN B cells (Figure 19 b). In contrast, LIT
spleen B cells from both groups of mice failed to increase expression of Foxp3 in the Teff cells
(Figure 19 c). Next, to examine whether the induction of Treg cells was dependent on the
secretion of TGF-β by LIT HLN B cells, we added TGF-β neutralizing Ab in the co-culture
system. The presence of the blocking Ab to TGF-β inhibited the expression of Foxp3 in Teff by
HLN B cells from both HEL and WT mice (Figure 19 d & e). These results demonstrate that B
cells isolated from HEL mice at LIT are capable of inducing Treg conversion in a TGF-β
dependent manner similar to those B cells from WT mice.

DISCUSSION
We have previously shown that regional B cells isolated from HLN of LIT mice are
capable of suppressing AAD in OVA sensitized recipient animals. This suppressive function is
exclusive to B cells from HLN of LIT mice and is not exerted by B cells from other lymphoid
tissues of mice at LIT or by HLN B cells of mice at AAD (85, 151). Bregs are shown to play an
important regulatory role not only in allergy and asthma but also in several other murine models
of autoimmune disorders such as EAE, SLE (216-218). B cell subsets expressing antiinflammatory cytokines such as IL-10 and TGF-β ex-vivo have been recently identified in
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humans with various diseases such as food allergy, multiple sclerosis, and rheumatoid arthritis
(219-223). With growing implications of Bregs in immune disorders and impending clinical
significance, it is important to study their characteristics and functions in further detail. The most
crucial question to address is whether Bregs are antigen-specific. Understanding this concept will
have long standing benefits in the clinical studies that adopt B cell therapies for human diseases.
In this study, we aimed at addressing the requirement of antigen-specific B cells for the
generation of local tolerance in our well established model of OVA-induced AAD. To this end,
we used transgenic HEL mice, 98% of whose peripheral B cells express BCR specific for HEL
protein (213). This serves as an elegant model to study the requirement of antigen-specific B
cells for development of LIT and to understand whether in our model, generation of Bregs
involves BCR stimulation or occurs as an effect of a suppressive milieu.
Our initial studies demonstrated that the airway (BAL) cellular components of naïve HEL
mice were similar to that of WT mice. When HEL mice were sensitized and challenged with
OVA, our data from the BAL confirmed airway eosinophilia in a similar manner as WT mice.
The lung compartments such as HLN and lung tissue also had prominent lymphocyte infiltration
with increased B cells and T cells at AAD as compared to naïve mice. This suggests that even in
the absence of BCR responses to OVA, AAD develops normally in the transgenic HEL mice as
the other components of the immune system such as macrophages, DCs and T cells respond
normally to OVA challenge. This observation correlates to our previous publication
demonstrating that B cells are not required for the development of AAD (85). The increase in B
cell number in the lung compartments especially the HLN of HEL mice at AAD implies by
stander B cell responses (non-OVA specific B cell response) to an ongoing pro-inflammatory
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condition. With normal development of AAD in the HEL mice, this model proved useful to
study the impact of antigen specific B cell responses specifically in the induction of LIT.
To study tolerance induction in HEL mice, OVA-sensitized transgenic mice were
subjected to chronic antigen exposure. We found that the HEL mice had resolved airway
eosinophilia completely at LIT with decreased number of T cells and B cells in HLN and lung
tissue at LIT as compared to AAD. Our data implicates the development of tolerance in HEL
mice, which is also in accordance with our previous findings in B cell deficient mice (85).
Hence, antigen specific B cell responses are not necessary to suppress detrimental proinflammatory responses and for the re-establishment of homeostasis in the airway of mice with
AAD.
Although tolerance develops normally in HEL mice, we observed diminished levels of
Foxp3+ Tregs in the HLN at LIT as compared to WT mice. This suggests that the induction of
Tregs by Bregs could be impaired in HEL mice. To address this, we performed in-vitro coculture experiments with B cells from HLN of LIT HEL mice and naive Teffs. We observed that
HEL B cells from HLN of mice at LIT were capable of inducing Treg conversion similar to the
Bregs from WT mice. In summary, our data implies that Bregs can be generated in a nonantigen- specific manner possibly by a tolerant milieu that develops during the course of
induction of tolerance in our model.
It is possible in our model that there are other cell types other than Bregs that act as the
key players to turn on the switch for induction of tolerance. A class of dendritic cells (DCs)
called the tolerogenic DCs, are recently known to be important players for establishing
peripheral tolerance (224). The role of tolerogenic DCs in alleviating disease symptoms by
induction of Tregs and causing T cell anergy is being well studied in several models of
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autoimmune disease (225). The airway epithelial cells, which are the first line of cells that come
in contact with the inhaled antigen, are also known to produce abundant levels of TGF-β upon
stimulation (226, 227). Another study with human bronchial epithelial cells shows that these
cells from healthy controls constitutively produce IL-10 which was down-regulated in
individuals with cystic fibrosis (228). It is possible that orchestration of several regulatory
mechanisms such as induction of tolerogenic DCs, regulatory B cells and secretion of antiinflammatory cytokines by airway epithelials etc, are coordinated simultaneously for the
development of LIT in our model; and they compensate for the absence of one cell type or
another. This theory also supports our previous finding where we showed (using B cell deficient
mice and adoptive transfer studies) that Bregs are sufficient but not necessary for suppressing
AAD and development of LIT (85).
A lot of attention in most on-going research has been focused on characterizing the
surface marker expression on regulatory B cells in mice and humans. To-date, there is not much
focus on understanding the antigen specificity of Bregs. Our study elaborated here, serves to be
one of the first investigations to demonstrate that antigen specific BCR responses are evitable for
the generation of regulatory B cells. Our finding may have significant clinical implications,
where Ag non-specific regulatory B cells can be generated in a culture dish by providing an
appropriate suppressive milieu (cytokines, tolerogenic DCs etc.) in-vitro (189, 229), and
extrapolated for use in clinical studies in a variety of autoimmune disorders and allergies.
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Figure 17. Changes in the number of WBCs in BAL of WT and HEL mice at naïve, AAD
and LIT stages of the model. Figure 15 depicts the total number of WBCs accumulated in the
BAL of WT and HEL mice. White bars represent WT C57BL/6 mice and black bars represent
HEL mice. The figure shows increased WBCs at AAD as compared to naïve and LIT stages; and
decreased WBCs at LIT as compared AAD in both WT and HEL mice. Significant changes in
the number of WBCs between naïve, AAD and LIT stages in WT mice were observed similar to
HEL mice. The data represent the mean ± s.e.m values, * p ≤ 0.02 between the respective stages
in HEL mice. n=6-8 mice per group
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Figure 18. Changes in the number of lymphocytes in HLN and lung of HEL and WT mice
at AAD and LIT. Figure 16 a and b represent data at AAD and Figure 16 c and d represent data
at LIT. White bars denote WT mice and black bars denote HEL mice. Panels a and b depict
increased accumulation of T cell subsets and B cells in the HLN (a) and lung tissue (b) of WT
and HEL mice correlating with increased eosinophils at AAD. Panels c and d depict similar
decrease in T cell subsets and B cells in the HLN (c) and lung tissue (d) of WT and HEL mice at
LIT correlating with decreased eosinophils and induction of tolerance in these mice. The naïve
HEL group is representative for both naïve WT and HEL mice for the respective subset of
lymphocytes. The data represent the mean ± s.e.m values.
# p < 0.005 between naïve HEL mice and WT or HEL mice at AAD or LIT stages for all
represented subsets.
!! p < 0.05 between naïve HEL mice and WT or HEL mice at LIT stage for all represented
subsets.
* p ≤ 0.05 as compared with WT mice. n=6-8 mice per group.
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Figure 19. LIT HLN B cells isolated from HEL mice induced formation of
CD4+Foxp3+ Treg cells from CD4+Foxp3− T effector cells. Panel a depicts pre-coculture
sample of wild-type CD4+CD25− T cells (naïve Teffs) which expressed very low levels (0.84%)
of Foxp3. Panels b, c and d represent in vitro coculture of naïve Teffs with B cells for 5 days in
the presence of anti-CD3 and anti-CD28 Ab, and evaluated for conversion to Foxp3+ T cells via
flow cytometry. Panel e depicts mean ± s.e.m values for each group calculated done in
triplicates. Coculture with LIT HLN B cells from WT and HEL mice (b) resulted in a greater
than 4 fold increase in Foxp3 expression, as compared with the other B cell populations (e).
Coculture of naïve Teff cells with LIT spleen B cells from WT and HEL mice resulted in
minimal intracellular Foxp3 expression on gated CD4+ cells (c). Addition of TGF-β neutralizing
Ab to the coculture significantly reduced the induction of Foxp3 expression (d). Results are
representative of an experiment, each done in triplicate. The data in e represent the mean ± s.e.m
values. * p ≤ 0.05 as compared with LIT HLN B cell group from WT and HEL mice. n = 5 mice
per group pooled together.
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BAL Analysis of WBCs in WT and HEL mice at Naïve, AAD and LIT Stages in the OVAInduced Murine Model of Asthma

Exposure

Total
Mice WBCs x104

WT

10.3 ± 2.4

Naïve
HEL

WT

16.1 ± 3.4

273 ± 54

AAD
HEL 249.2 ± 76.3

WT

64.6 ± 13

LIT
HEL 53.3 ± 12.1

Macrophages
x104

PMNs #
X104

Lymphocytes
x104

Eosinophils
x104

(%)

(%)

(%)

(%)

9.9 ± 2

0

0.3 ± 0.1

0

(96 ± 1)

0

(3 ± 1)

0

15.7 ± 3

0.02

0.3 ± 0.1

0.01

(97 ± 1)

(0.2 ± 0.2)

(2 ± 1)

(0.2 ± 0.2)

21 ± 6

3.5 ± 2

30 ± 8

218 ± 45

(8.7 ± 2)

(1.5 ± 1)

(10 ± 2)

(79 ± 3)

42 ± 17

21 ± 8

17.3 ± 5

188 ± 66

(25.2* ± 7)

( 11* ± 4)

(11 ± 3)

(58.5 ± 11)

49.8 ± 10

9.5 ± 3

3.8 ± 1

1.4 ± 0.3

(78.5 ± 2)

(13 ± 2)

( 6.4 ± 1)

(2.4 ± 1)

37.4 ± 8

10 ± 4

5.3 ± 2

0.4 ± 0.2

( 73 ± 7)

(16.3 ± 5)

(10 ± 2)

(0.9 ± 0.3)

Table 2.
#

Polymorphomononuclear cells

Data represent the mean ± s.e.m values; * indicates p < 0.05 as compared to WT mice; n = 6-8.
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CHAPTER 6

OVERALL DISCUSSION AND FUTURE DIRECTIONS

i) Tolerance driven by the “local” draining lymph node

Asthma is a complex disease. Its generation and resolution, pathogenesis and regulation
are dependent upon intricate interactions between adaptive and innate immune cells. In animal
models, antigen-induced AAD constitutes an unwanted and unnecessary Th2-driven
inflammatory reaction against harmless inhaled antigens. Several murine models have been
developed to establish Th2 driven AAD; and the majority of work focuses on understanding the
mechanisms of disease development and identifying intervention strategies to prevent disease
progression. In our laboratory we have a unique approach to this problem, our model of asthma
which allows us to study disease progression and its spontaneous resolution in (114). In this
model the inhibition to inflammatory responses and establishment of homeostasis occurs locally
without hampering T cell and B cell responses outside of the lung compartments (118, 195).
The HLN which is the regional draining lymph node of the respiratory tract is very
important to the establishment and resolution of OVA-induced AAD. In general, lymph nodes
are highly organized structures that are positioned at critical anatomical locations to be quick to
respond and protect the host against infections. Lymph nodes of the mucosa are of special
importance as they are continually bombarded with dietary Ag in the intestines and inhaled Ag in
the lung. Within these lymphoid structures, orchestrated movement and interactions between
several types of immune and non-immune cells dictate the course of an ongoing inflammatory
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response. In our model, the size of the HLN increases prominently with a multi-fold increase in
total cell numbers at AAD. This phenomenon is not observed in systemic lymph nodes (114,
195). It is also established from the work discussed in this thesis that other mucosal regions such
as the gastro-intestinal tract (see Chapter 4) do not participate in the ongoing allergic airway
inflammation or resolution, suggesting that the response is local to the lung.
During LIT, although there is a decrease in the size and cell number in the HLN
compared to AAD, the lymphocytic populations are still maintained, implying a rather active
state of the lymph node despite the resolution of inflammation. There is also a shift in the
signature of these lymphocytes from a pro-inflammatory state at AAD to an anti-inflammatory
(regulatory) state at LIT. This is evidenced by the accumulation of Foxp3+ Tregs and CD5+
Bregs which play an important role in tolerance via TGF-β dependent mechanisms (85, 151). We
also observed changes in the trafficking patterns of the regulatory cells during the establishment
of tolerance in the HLN; with preferential localization of the Tregs in B cell follicles (via
confocal microscopy) towards LIT where the majority of the Bregs also reside. This suggests
possible interactions of these regulatory cells with each other and other cell types crucial to the
development of tolerance. With changes in cell signatures transitioning from AAD to LIT and
changes in trafficking patterns, it is likely that the events governing the establishment of LIT are
orchestrated in the HLN.
On the flip-side, it not clear yet if the events in the lung tissue are likely to play an
important for the transitioning from AAD to LIT. In the lung tissue there is formation of B cell
and T cell clusters called TELT (tertiary ectopic lymphoid tissue) at AAD. Towards LIT these
clusters disappear with more Tregs in the lung. These changes in lymphocytic populations also
suggest that the lung tissue itself could be actively involved in the resolution of AAD (207). It is
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possible that the cells present in the lung tissue such as the airway epithelial cells, the lung DCs
or the macrophages that are constantly exposed to Ag insult, turn on the molecular switch that
shuts down inflammation (at time points between peak inflammation and early phase of
tolerance establishment); which could influence the HLN to accelerate the shift towards
resolution of inflammation. Experiments are underway in the laboratory to define the critical
elements in the HLN and lung that mediate the shift from AAD to LIT and to determine if it
originates in the lung tissue itself or the HEL. It is possible that the signals is initiated in the
HLN and lymphocyte trafficking is uni-directional from the HLN to the lung tissue.

ii) Regulatory B cells: their important role in development of immunological tolerance

LIT represents one process by which mice are able to suppress this detrimental
inflammatory response and re-establish airway homeostasis despite ongoing systemic responses.
It is apparent, both from basic science and clinical stand points, that no one cell type – effector or
regulatory – stands alone in this disease and is able to create or prevent asthma. From our work,
it is evident that suppressive B cells that are local to the lung compartments have the ability to
suppress the development of airway inflammation and turn off the on-going local inflammatory
responses. However, studies have also shown the B-cell knockout animals develop LIT; they do
so despite diminished levels of regional Foxp3+ Tregs (85, 86). This finding supports the
complex interactions of Bregs and Tregs in the development of tolerance in WT animals. The
contrasting pro- and anti-inflammatory roles of B and T cells are likely to overlap in asthma,
with the balance of these opposing actions determining the natural course of the disease.
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Another important conclusion from the work presented in this thesis is that B cells that
are devoid of antigen specificity could potentially develop suppressive functions from the
tolerant milieu prevalent towards LIT. Our studies show that HEL mice which lack OVAspecific B cell responses, develop AAD and LIT in a similar manner as WT mice. The B cells
from the HLN of the HEL mice at LIT are also capable of converting Foxp3- Teffs to Foxp3+
Tregs in-vitro similar to Bregs from WT mice. This study provides important information about
the nature of these Bregs in that they may be induced in an antigen non-specific manner. Thus,
we have identified a subpopulation of B cells that arose preferentially in regional lymphoid
tissues in response to inflammation and chronic antigen exposure. Further analysis of the genesis
and function of these TGF-producing Bregs will help us understand how mice are capable of
modulating their AAD and, thereby, yield potential insights into new therapeutic approaches for
the management of asthma. Future experiments focused on generating Bregs in-vitro under
appropriate culture conditions are also necessary as they will have greater clinical implications,
for restoring tolerance in patients to control Th-2 driven inflammatory responses.

iii) Future Directions

Mechanisms of LIT

Where is tolerance initiated and orchestrated? As discussed above examining the role of
the HLN and lung in establishing tolerance in our model of asthma is a very important question
and has yet to be addressed definitively. Exploring these mechanisms would help us identify
subsets of cells which are crucial for initiating and orchestrating tolerance. Our data clearly
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indentifies the roles of regulatory T cells and B cells in the HLN for developing immunological
tolerance. In our model of allergic asthma, we strongly believe that there are multiples cell types
and pathways involved; and understanding each of their contributions for the development of
tolerance is an exciting venue for developing improved immune-therapies.
Is it the HLN? Do cells that regulate the development of LIT emerge from the HLN,
traffic into the lung tissue and dictate the switch over towards tolerance? This question can be
addressed by stopping the egress of cells out of the HLN into the lung tissue at different time
points between peak inflammation and establishment of tolerance, as the events governing LIT
may begin as soon as AAD sets in or at an intermediate stage. This study can be achieved by
treating mice with the drug FTY720, which prevents egress of lymphocytes from lymphoid
tissues (230, 231) at D 7, 14, 21 or 28 after OVA aerosols.
Another important study is to determine whether the localization of Tregs and Bregs in
the follicles is crucial for the development of LIT. (232). Thus administering this Ab at
intermediate time points between AAD and LIT and studying the development of
tolerance would help understand the importance of preferential localization of Tregs
within the follicles and T cell – B cell border towards LIT and orchestrated trafficking of
T cells and B cells into the follicles.
Is TELT driving inflammation or resolution or both? B cell and T cell clusters that are
formed in the lung tissue at AAD are replaced by mostly Tregs and fewer B and T cells at LIT
(77, 195). It is possible that cellular interactions in the lung tissue are mostly governing the
establishment of LIT. Quantifying the number of Tregs in the lung at intermediate time points
between AAD and LIT using flow cytometry and defining their location relative to the TELT via
confocal microscopy, will help determine whether the cell clusters in the lung tissue are
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composed of effector T and B cells at AAD and if they are being replaced by regulatory cells
towards tolerance. Comparing these data from the lung with the HLN at the corresponding stages
will help understand where the switch over to resolution begins. The study using FTY720
treatment will also address involvement of lung tissue in establishing tolerance. If we observe the
development of tolerance despite preventing lymphocyte trafficking from the lymph nodes to the
lung tissue, it would suggest a more prominent role of lung tissue in development of tolerance.

Describing regulatory B cells

What is the function of the surface marker CD5? Bregs in our model are identified by the
presence of the surface marker CD5. Understanding the function of CD5 on Bregs is important to
be able to exploit the therapeutic uses of Bregs. CD5 is expressed on activated T cells (233) and
“innate-like” B cells called B1 cells which are spontaneous producers of natural IgM antibodies
(234). The function of CD5 on T cells has been well characterized, although somewhat
controversial. Several investigations demonstrate that T cell – B cell interaction via CD5-CD72
binding along with CD3-TCR stimulation results in proliferation of T cells and IL-2 secretion
(235, 236). The CD5-CD72 interaction has also been shown in experiments using B cells isolated
from patients with chronic lymphocytic leukemia to be involved in B cell activation and
proliferation (237). On the contrary, some studies also show CD5 has an ITIM-like motif and
stimulation of CD5 activated T cells results in down-regulation of Ca2+ mobilization and
decreased IL-2 secretion (238). It is possible that CD5 signaling activates T cells early on in an
immune response and later serves as a negative stimulator as a mechanism to prevent prolonged
T cell responses. However, the role of CD5 signaling in the context of regulatory B cells has not
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been studied in detail, especially in our model where the suppressive function by Bregs is
mediated via TGF-β. This can be achieved by examining whether Bregs (HLN B cells from LIT
mice) isolated from CD5-/- mice are capable of suppressing the development of AAD in adoptive
transfer studies. Over expression of CD5 regulating genes or their silencing will also provide
novel methods to establish the role of CD5 on Bregs.
Can we generate Bregs in-vitro? It has been shown in studies with B cells isolated from
human PBMCs that CD5 expression can be induced on CD5- B cells when cultured in-vitro
along with T cells and appropriate stimuli such as CD40 ligation (using anti-CD40 Abs (189,
239)). Another study identifies the novel function of B-cell activation factor (BAFF) in the
induction of regulatory B cells. They have demonstrated that treating B cells with BAFF in-vitro
led to the expansion of B cells that are CD5+ and CD1dhi. These B cells were also capable of
producing IL-10 after treatment with BAFF, and this effect was abrogated by neutralizing BAFF
with TACI-Fc antibody (229). An important study using our model will be to stimulate B cells
in-vitro with a variety of stimuli such as CD40 ligation, BAFF etc; inducing CD5 expression and
then to assess their ability in suppressing the development of AAD.
Do Bregs interact with other immune cells? Studies have shown that Bregs can inhibit Ag
presentation on APCs by secretion of IL-10 (240, 241). In colitis models it has been
demonstrated that Bregs interact with and suppress the functions of CD8 T cells and NKT cells
(161, 242). In our model, we have described a unique function of Bregs which is the induction of
Foxp3+ Tregs from Foxp3- Teff cells. It is likely that the Bregs in our model also elicit other
suppressive functions by interacting with immune cells such as APCs and CD8 T cells, which is
yet to be studied.
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Other interacting molecules: Among the key questions that are still to be addressed are
related to the molecular interactions of Bregs. Several publications have shown that CD40CD40L interactions between Bregs and T cells are important for their suppressive functions
(145, 243). Interaction of PD-L1 on Bregs with PD-1 is demonstrated to be crucial for mediating
protection against the development of EAE (244, 245). Such molecular interactions mediating
the interactions between Bregs and other subsets of cells need to be further studied. Breg cells
clearly represent an interesting field of research with multiple clinical implications and possess
tremendous scope for therapeutic development.

iv) Working model for events establishing LIT
Our hypothesis proposes that the conversion of T effector cells (CD4+ Foxp3-) to Foxp3+
regulatory T cells occurs in the B cell follicles of the HLN and is mediated by regulatory B cells.
Several events related to changes in trafficking and interaction of lymphocytes during the
transition from AAD to LIT are illustrated in the following paradigm (Figure 20).

A. Naïve/Sensitized: The lung compartments of naïve and sensitized mice are relatively
quiescent, with a relatively small HLN consisting of a fewer B cell follicles (B cells) and smaller
T cell zone (T cells). As we and others have shown, the majority of the WBCs in the lung at
these stages are macrophages with a few T and B cells. As in other organs, there is constant
circulation of DCs and naïve lymphocytes between the blood stream, peripheral tissue – in this
case the lung, lymph nodes (HLN) and back to the blood (246-248). This process of lymphocyte
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recirculation provides an effective mechanism of immune surveillance inspecting for the entry of
pathogens through the process of breathing.

B. Allergic Airway Disease: Acute daily exposure of OVA for 7 days results in inflammation
which is characterized by the recruitment of effector T cells and B cells and eosinophils to the
lung. During this process, the DCs that are “primed,” phagocytose, process and present the OVA
Ag in the airway submucosa, then migrate to the HLN, where they present the OVA Ag to Agspecific T cells. Activated CD4+ and CD8+ T cells proliferate and migrate out of the HLN to the
lung and drive a Th2 type immune response. Effector B cells undergo maturation in the germinal
centers within the HLN and with CD4+ T cells help produce massive amounts of IgE antibody
most of which are OVA-specific at AAD (249, 250). The size of the HLN increases several fold
and at this stage consists of larger B cell follicles that are increased in number and size as
compared to those at the naïve or sensitized stage (151, 195). Notably, at AAD, Tregs in the B
cell follicles and T cell zones of the HLN or in the lung tissue are reduced in number as
compared to LIT. Eosinophil trafficking into the lung tissue is increased significantly at AAD. At
this stage, we observe the formation of B and T cell aggregates in the lung tissue referred to as
tertiary ectopic lymphoid tissue (TELT) which were absent in sensitized mice. These aggregates
were present but smaller after 3 days of OVA aerosols and were largest at peak AAD. They
began to diminish after 14 days of OVA exposure (207).

C. Local Inhalational Trafficking: Continuous daily Ag exposure for 42 days results in the
resolution of AAD and development of LIT. With the resolution of inflammation, the size of the
HLN becomes smaller as compared to that at AAD; although remains noticeably larger than in a
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naïve or sensitized mouse. B cell follicles are also smaller at LIT but are infiltrated with Tregs.
We have demonstrated that CD5+ B cells isolated from HLN of mice at LIT express TGF-β on
their surface and are capable of suppressing the development of AAD and converting Teff cells
into Foxp3+ Tregs; and are thus regulatory. We have also shown that increased numbers of CD5+
Bregs and Foxp3+ Tregs localize in the B cell follicles at LIT as compared to AAD (see Figure
8, Chapter 3). Using confocal microscopy we have shown qualitatively and quantitatively that
Tregs preferentially traffic to the T cell – B cell border and B cell follicles of the HLN at LIT
(see Figure 7, Chapter 3). This suggests the possible induction of Tregs by Bregs in the follicular
regions of HLN during development of tolerance. At LIT, the composition of WBCs in the lung
tissue is almost restored to normal with majority of macrophages. Although, we still observe a
few B cell – T cell aggregates that are much smaller as compared to AAD. At LIT, there are is a
significant increase in the number of Tregs and Bregs in the HLN and lung tissue which shift the
balance from a pro-inflammatory condition to a regulatory state more representative of normal
homeostasis.
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Figure 20. Paradigm for the establishment of LIT
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